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A B S T R A C T
Background
Sore throat is a common reason for people to present for medical care. Although it remits spontaneously, primary care doctors commonly
prescribe antibiotics for it.
Objectives
To assess the benefits of antibiotics for sore throat for patients in primary care settings.
Search methods
We searched CENTRAL 2013, Issue 6, MEDLINE (January 1966 to July week 1, 2013) and EMBASE (January 1990 to July 2013).
Selection criteria
Randomised controlled trials (RCTs) or quasi-RCTs of antibiotics versus control assessing typical sore throat symptoms or complications.
Data collection and analysis
Two review authors independently screened studies for inclusion and extracted data. We resolved differences in opinion by discussion.
We contacted trial authors from three studies for additional information.
Main results
We included 27 trials with 12,835 cases of sore throat. We did not identify any new trials in this 2013 update.
1. Symptoms
Throat soreness and fever were reduced by about half by using antibiotics. The greatest difference was seen at day three. The number
needed to treat to benefit (NNTB) to prevent one sore throat at day three was less than six; at week one it was 21.
2. Non-suppurative complications
The trend was antibiotics protecting against acute glomerulonephritis but there were too few cases to be sure. Several studies found
antibiotics reduced acute rheumatic fever by more than two-thirds within one month (risk ratio (RR) 0.27; 95% confidence interval
(CI) 0.12 to 0.60).
3. Suppurative complications
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Antibiotics reduced the incidence of acute otitis media within 14 days (RR 0.30; 95% CI 0.15 to 0.58); acute sinusitis within 14 days
(RR 0.48; 95% CI 0.08 to 2.76); and quinsy within two months (RR 0.15; 95% CI 0.05 to 0.47) compared to those taking placebo.
4. Subgroup analyses of symptom reduction
Antibiotics were more effective against symptoms at day three (RR 0.58; 95% CI 0.48 to 0.71) if throat swabs were positive for
Streptococcus, compared to RR 0.78; 95% CI 0.63 to 0.97 if negative. Similarly at week one the RR was 0.29 (95% CI 0.12 to 0.70)
for positive and 0.73 (95% CI 0.50 to 1.07) for negative Streptococcus swabs.
Authors’ conclusions
Antibiotics confer relative benefits in the treatment of sore throat. However, the absolute benefits are modest. Protecting sore throat
sufferers against suppurative and non-suppurative complications in high-income countries requires treating many with antibiotics for
one to benefit. This NNTB may be lower in low-income countries. Antibiotics shorten the duration of symptoms by about 16 hours
overall.
P L A I N L A N G U A G E S U M M A R Y
Antibiotics for people with sore throats
Question
This review sought to determine whether antibiotics are effective for treating the symptoms and reducing the potential complications
associated with sore throats.
Background
Sore throats are infections caused by bacteria or viruses. People usually recover quickly (usually after three or four days), although
some develop complications. A serious but rare complication is rheumatic fever, which affects the heart and joints. Antibiotics reduce
bacterial infections but they can cause diarrhea, rash and other adverse effects and communities build resistance to them.
Study characteristics
The review is current to July 2013 and included 27 trials with 12,835 cases of sore throat. All of the included studies were randomised,
placebo-controlled trials which sought to determine if antibiotics helped reduce symptoms of either sore throat, fever and headache or
the occurrence of more serious complications. Studies were conducted among both children and adults.
Key results
The review found that antibiotics shorten the duration of pain symptoms by an average of about one day and can reduce the chance
of rheumatic fever by more than two-thirds in communities where this complication is common. Other complications associated with
sore throat are also reduced through antibiotic use.
Quality of evidence
The quality of the included studies was moderate to high. However, there were very few recent trials included in the review (only three
since 2000), hence it is unclear if changes in bacterial resistance in the community may have affected the effectiveness of antibiotics.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Antibiotics compared with placebo for sore throat
Patient or population: pat ients present ing with sore throat
Settings: community
Intervention: ant ibiot ics
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Antibiotics Placebo
Sore throat: day 3 0.66 0.72 0.68 to 0.76 3621 (15) High
Sore throat: day 7 0.18 0.65 0.55 to 0.76 2974 (13) High
Rheumatic fever 0.017 0.29 0.18 to 0.44 10,101 (16) High Based largely on risk in
pre-1960 trials
Glomerulonephrit is 0.001 0.22 0.07 to 1.32 5147 (10) Low Sparse data: 2 cases
only
Quinsy 0.023 0.14 0.05 to 0.39 2433 (8) High
Otit is media 0.02 0.28 0.15 to 0.52 3760 (11) High
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; RR: risk rat io
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
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B A C K G R O U N D
Description of the condition
Sore throat is a very common reason for people to attend primary
care settings (ABS 1985). Moreover, four to six times as many
people suffering sore throat do not seek care (Goslings 1963;
Horder 1954). Sore throat is a disease that remits spontaneously,
that is, ’cure’ is not dependent on treatment (Del Mar 1992c).
Nonetheless, primary care doctors commonly prescribe antibiotics
for sore throat and other upper respiratory tract infections. There
are large differences in clinical practice between countries (Froom
1990) and between primary care doctors (Howie 1971).
Description of the intervention
The administration of antibiotics is likely to shorten the time to
the remittance of symptoms and reduce the likelihood of compli-
cations in patients whose sore throat has a bacteriological aetiol-
ogy (van Driel 2013). However, their benefits may be limited in
the treatment of sore throat more generally (Reveiz 2013). Tra-
ditionally, doctors have attempted to decide whether the cause of
the infection is bacterial, especially when caused by the group A
beta-haemolytic Streptococcus (GABHS) (which can cause acute
rheumatic fever and acute glomerulonephritis). However, decid-
ing the aetiological agent is difficult (Del Mar 1992b).
How the intervention might work
Antibiotics target bacteria which are potentially responsible for
sore throat symptoms and possible subsequent suppurative and
non-suppurative sequelae. Successful eradication of bacteria may
promote faster healing andpreventionof secondary complications.
However, not all sore throat cases are of bacteriologic origin and
bacteriamay resist antibiotic treatmentwhich could limit the over-
all effectiveness of the intervention.
Why it is important to do this review
Whether or not to prescribe antibiotics for sore throat is contro-
versial. The issue is important because it is a very common dis-
ease and differences in prescribing result in large cost differences.
Moreover, increased prescribing increases patient attendance rates
(Howie 1978; Little 1997). This review is built on an early meta-
analysis (Del Mar 1992a) and is an update of previous Cochrane
Reviews (Del Mar 1997; Del Mar 2000; Del Mar 2004; Del Mar
2006; Spinks 2009).
O B J E C T I V E S
To assess the benefits of antibiotics for sore throat for patients in
primary care settings.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) or quasi-RCTs.
Types of participants
Patients presenting to primary care facilities with symptoms of
sore throat.
Types of interventions
Antibiotics or placebo control.
Types of outcome measures
Primary outcomes
1. Symptoms of sore throat on day three.
2. Symptoms of sore throat at one week (days six to eight).
Secondary outcomes
1. Symptoms of fever at day three.
2. Symptoms of headache at day three.
3. Incidence of suppurative complications:
i) quinsy;
ii) acute otitis media;
iii) acute sinusitis.
4. Incidence of non-suppurative complications:
i) incidence of acute rheumatic fever within two months;
ii) acute glomerulonephritis within one month.
Search methods for identification of studies
Electronic searches
For this update we searched the Cochrane Central Register
of Controlled Trials (CENTRAL) 2013, Issue 6, part of The
Cochrane Library, www.thecochranelibrary.com (accessed 11 July
2013), which contains the Cochrane Acute Respiratory Infections
Group’s Specialised Register, MEDLINE (May 2011 to July week
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1, 2013) and EMBASE (May 2011 to July 2013). See Appendix
1 for details of previous searches.
MEDLINE and CENTRAL were searched using the search strat-
egy shown below.We combined theMEDLINE search string with
the Cochrane Highly Sensitive Search Strategy for identifying ran-
domised trials in MEDLINE: sensitivity and precision-maximis-
ing version (2008 revision) (Lefebvre 2011).We adapted the search
string for EMBASE (Appendix 2). There were no language or pub-
lication restrictions.
MEDLINE (Ovid)
1 exp Pharyngitis/
2 pharyngit*.tw.
3 exp Nasopharyngitis/
4 (nasopharyngit* or rhinopharyngit*).tw.
5 exp Tonsillitis/
6 tonsillit*.tw.
7 (tonsil* adj2 (inflam* or infect*)).tw.
8 ((throat* or pharyn*) adj3 (infect* or inflam* or strep*)).tw.
9 (sore* adj2 throat*).tw.
10 or/1-9
11 exp Anti-Bacterial Agents/
12 antibiot*.tw,nm.
13 (azithromycin* or clarithromycin* or erythromycin* or rox-
ithromycin* or macrolide* or cefamandole* or cefoperazone*
or cefazolin* or cefonicid* or cefsulodin* or cephacetrile* or
cefotaxime* or cephalothin* or cephapirin* or cephalexin* or
cephaclor* or cephadroxil* or cephaloglycin* or cephradine* or
cephaloridine* or ceftazidime* or cephamycin* or cefmetazole*
or cefotetan* or cefoxitin* or cephalosporin* or cefpodoxime*
or cefuroxime* or cefixime* or amoxicillin* or amoxycillin* or
ampicillin* or sulbactum* or tetracyclin* or clindamycin* or
lincomycin* or doxycyclin* or fluoroquinolone* or ciprofloxa-
cin* or fleroxacin* or enoxacin* or norfloxacin* or ofloxacin* or
pefloxacin* or moxifloxacin* or esparfloxacin* or clindamicin*
or penicillin* or ticarcillin* or beta-lactam* or levofloxacin* or
trimethoprim* or co-trimoxazole).tw,nm.
14 or/11-13
15 10 and 14
Searching other resources
We searched ClinicalTrials.gov and WHO ICTRP (11 July 2013)
for completed and ongoing trials. We hand-checked references of
selected studies and relevant reviews to find additional studies.
Data collection and analysis
Selection of studies
Two review authors (AS, CD) independently screened abstracts
of potential studies and retrieved full articles for those that were
trials. Two review authors (AS, CD) examined the full articles and
either selected for inclusion or rejected to the excluded studies list.
We resolved differences in opinion by discussion.
Data extraction and management
Two review authors (AS, CDM) independently extracted data
from the included studies based on patient-relevant outcomes:
namely the complications and symptoms listed above. Data ex-
traction involved reading from tables, graphs and, in some cases,
contacting trial authors for raw data (Dagnelie 1996; Little 1997;
Zwart 2000; Zwart 2003).
Assessment of risk of bias in included studies
We assessed risk of bias according to the approach indicated in the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011). We used the following six criteria: adequate sequence gen-
eration, allocation concealment, blinding, incomplete outcome
data, selective reporting and other bias.
Measures of treatment effect
All treatment effect outcomes were dichotomous data, reported
as risk ratios (RR). We reported occurrence of complications dur-
ing the study period for suppurative and non-suppurative com-
plications. We assessed the presence of symptoms (sore throat,
fever, headache) when possible at day three and week one (days six
to eight). We also calculated numbers needed to treat to benefit
(NNTB) for the primary outcomes.
Dealing with missing data
We performed an intention-to treat (ITT) analysis for all out-
comes.
Assessment of heterogeneity
We assessed heterogeneity by using the Chi2 test with the signifi-
cance level set at 0.1.We determined the effect of heterogeneity by
the I2 statistic which indicates the proportion of total variability
which can be explained by heterogeneity.We interpreted values of
the I2 statistic greater than 50% as indicating substantial hetero-
geneity, in accordance with the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011).
Data synthesis
We combined data where possible in order to perform meta-anal-
yses to report RR for all relevant outcomes. We used a random-
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effects meta-analytical method (Mantel-Haenszel) in order to ac-
count for heterogeneity that was detected using the methods de-
scribed above. Not all studies were able to contribute data to each
of the meta-analyses performed.
Subgroup analysis and investigation of heterogeneity
We performed a series of subgroup analyses to assess the differ-
ences in outcomes across various subgroups within the participant
population:
1. treatment with penicillin (omitting other antibiotics);
2. children compared with adults;
3. positive throat swab versus negative throat swab versus
untested and/or inseparable data for group A beta-haemolytic
Streptococcus (GABHS).
Sensitivity analysis
We performed sensitivity analyses to assess the degree to which
results were influenced by the following criteria:
1. early (pre-1975) versus later (post-1975) studies;
2. blinded versus unblinded studies;
3. antipyretics administered versus no antipyretics
administered.
R E S U L T S
Description of studies
Results of the search
A total of 61 studies were considered for the review. Of these,
there were 27 controlled studies that met the inclusion criteria and
were included in the review. There were no new trials included in
this 2013 update. However, three new trials were considered and
subsequently excluded.
Included studies
The included studies investigated a total of 12,835 cases of sore
throat. The majority of studies were conducted in the 1950s, dur-
ing which time the rates of serious complications (especially acute
rheumatic fever) were much higher than today. Seven studies pub-
lished in the last 15 years (between 1996 to 2003) were included.
However, no new studies have been published since 2003.
The age of participants ranged from less than one year to older
than 50 years. The participants of eight early studies were young
male recruits from the United States Air Force (Brink 1951;
Brumfitt 1957; Catanzaro 1954; Chamovitz 1954; Denny 1950;
Denny 1953; MacDonald 1951; Wannamaker 1951). Seven of
the remaining studies recruited children up to 18 years of age
only (El-Daher 1991; Krober 1985; Nelson 1984; Pichichero
1987; Siegel 1961; Taylor 1977; Zwart 2000), three recruited
only adults or adolescents aged 15 years or over (Howe 1997;
Petersen 1997; Zwart 2003) and nine studies recruited both adults
and children (Bennike 1951; Chapple 1956; Dagnelie 1996; De
Meyere 1992; Landsman 1951; Leelarasamee 2000; Little 1997;
Middleton 1988; Whitfield 1981).
All studies recruited patients presenting with symptoms of sore
throat. The majority of studies did not distinguish between
bacterial and viral aetiology. However, seven studies included
or analyzed results for group A beta haemolytic Streptococcus
(GABHS) positive patients only (Catanzaro 1954; De Meyere
1992; El-Daher 1991; Krober 1985; Middleton 1988; Nelson
1984; Pichichero 1987), one study distinguished differences
in outcomes between GABHS-positive and negative patients
(Dagnelie 1996) and two studies specifically excludedpatientswho
were GABHS-positive (Petersen 1997; Taylor 1977).
Excluded studies
The most common reason for exclusion was lack of appropriate
control group (n = 13).Other reasons for exclusionwere: irrelevant
or non-patient centred outcomes (n = 6), main complaint other
than acute sore throat (n = 6), inappropriate or no randomisation
to treatment (n = 5), an intervention other than antibiotics was
being tested (n = 2), the study tracked natural course of illness
only (n = 1) or that the study reported previously published data
already included (n = 1).
Risk of bias in included studies
The overall risk of bias is presented graphically in Figure 1 and
summarised in Figure 2.
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Figure 1. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
In most early studies, participants were randomised to treatment
and control groups by methods that could potentially introduce
bias (for example, Air Force serial number, drawing a card from a
deck, hospital bed number) or not randomised at all. Allocation
methods were generally appropriate in the later studies.
Blinding
Eighteen of the studies were double-blinded and three were single-
blinded.
Incomplete outcome data
Outcome data were complete for nearly all studies. For one study
it was not clear how many participants maintained pain score
diaries and some participants who were initially randomised were
excluded due to being GABHS-positive (Petersen 1997).
Other potential sources of bias
The use of antipyretic analgesics was not stated in nine studies, ad-
ministered routinely in five studies and prohibited in four studies.
The prohibition of analgesics might exaggerate any small symp-
tomatic benefit of antibiotics over control if antipyretic analgesics
are usually recommended in normal practice.
Effects of interventions
See: Summary of findings for the main comparison
Primary outcomes
1. Symptoms of sore throat on day three
At day three of the illness, antibiotics reduced symptoms of sore
throat (risk ratio (RR) 0.68; 95% confidence interval (CI) 0.59
to 0.79) (Analysis 1.1). Day three was the greatest time of benefit
because the symptoms of only half the participants had settled.
2. Symptoms of sore throat at one week (days six to eight)
At one week (six to eight days) the RR of experiencing sore throat
was 0.49 (95% CI 0.32 to 0.76) (Analysis 1.5), although 82% of
controls were better by this time.
Secondary outcomes
1. Symptoms of fever at day three
At day three of the illness, antibiotics reduced symptoms of fever
(RR 0.71; 95% CI 0.45 to 1.10) (Analysis 2.1).
2. Symptoms of headache at day three
At day three of the illness, antibiotics reduced symptoms of
headache (RR 0.44; 95% CI 0.27 to 0.71) (Analysis 3.1).
3. Incidence of suppurative complications
Antibiotics reduced the incidence of acute otitis media to about
one-third of that in the placebo group (RR 0.30; 95% CI 0.15 to
0.58) (Analysis 4.4) and reduced the incidence of acute sinusitis
to about one-half of that in the placebo group (RR 0.48; 95%
CI 0.08 to 2.76) (Analysis 4.6). Data indicate that the incidence
of quinsy was also reduced in relation to the placebo group (RR
0.15; 95% CI 0.05 to 0.47) (Analysis 4.7).
4. Incidence of non-suppurative complications
Cases of acute glomerulonephritis only occurred in the control
group which suggests protection by antibiotics. However, there
were only two cases andonly 10 studies reported on acute glomeru-
lonephritis as an endpoint. Therefore, our estimate of the pro-
tection has a very wide 95% CI (RR 0.22; 95% CI 0.02 to
2.08) (Analysis 4.8) which precludes us from definitively claiming
that antibiotics protect sore throat sufferers from acute glomeru-
lonephritis.
Several studies found benefit from antibiotics for acute rheumatic
fever which reduced this complication to about one-quarter of that
in the placebo group (RR 0.27; 95% CI 0.12 to 0.60) (Analysis
4.1). Few studies examined antibiotics other than penicillin. Con-
fining the analysis to penicillin alone resulted in no difference in
estimated protection (RR 0.27; 95% CI 0.14 to 0.50) (Analysis
4.2).
Subgroup analysis of symptom reduction
1. Blind versus unblinded studies
There was no significant difference between blinded and un-
blinded studies for symptoms of sore throat at day three (RR 0.65;
95% CI 0.54 to 0.78 and RR 0.79; 95% CI 0.60 to 1.05, respec-
tively) (Analysis 1.2) nor at one week (RR 0.62; 95% CI 0.38 to
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1.03 and RR 0.30; 95% CI 0.08 to 1.15, respectively) (Analysis
1.6). Contrary to expectation, the trend was for a greater effect of
antibiotics for blind studies at day three.
2. Antipyretics administered versus not administered
Use of antipyretics led to no significant difference between studies
in which antipyretics were offered and those in which they were
not (RR 0.52; 95% CI 0.33 to 0.81 and RR 0.62; 95% CI 0.55
to 0.70, respectively) (Analysis 1.3).
3. Throat swabs positive for Streptococcus versus negative
for Streptococcus versus not tested and/or inseparable
combined data
The probability of still experiencing pain on day three is slightly
more than one-half (RR 0.58; 95% CI 0.48 to 0.71) for those
participants who had positive throat swabs for GABHS, compared
to three-quarters (RR 0.78; 95% CI 0.63 to 0.97) for those with
negative swabs (Analysis 1.4). There was a similar effect at one
week (RR 0.29; 95% CI 0.12 to 0.70 and RR 0.73; 95% CI 0.50
to 1.07, respectively) (Analysis 1.7). That is, the effectiveness of
antibiotics is increased in people with Streptococci growing in the
throat.
4. Children versus adults
There were few studies that included children (younger than 13
years of age): only 61 cases in total for when fever was evaluated
at day three. There was overlap of the RR 95% CI, so that the
trend for children to not experience benefits was not significantly
different to adults who did (RR 1.27; 95% CI 0.76 to 2.13 and
RR 0.29; 95% CI 0.06 to 1.51, respectively) (Analysis 2.3).
Some of these results are summarised in Figure 3.
Figure 3. Summary of findings.
A trial from Thailand was included in the 2003 update (
Leelarasamee 2000). It is especially important because it is one
of the few trials from a non-Western industrial country. Unfortu-
nately we were unable to enter its data into the meta-analysis be-
cause of different ways of collecting the data (in particular no data
were collected mid-way through the illness). Nevertheless, the use
of antibiotics conferred no benefit (nor harms) on symptoms or
complications.
D I S C U S S I O N
Natural history
In the placebo groups, after three days symptoms of sore throat and
fever had disappeared in about 40%and 85%, respectively. Eighty-
two percent of participants were symptom-free by one week. This
natural history was similar in Streptococcus-positive, negative and
untested participants. About 1.7 per 100 placebo participants
developed rheumatic fever. However, this complication occurred
only in trials reporting before 1961. The background incidence
of acute rheumatic fever has continued to decline in Western so-
cieties since then.
Benefits of treatment
The absolute benefit of antibiotics for the duration of symptoms
was modest. The reduction of illness time is greatest in the middle
of the illness period when the mean absolute reduction is about
one day at around day three. There are not enough data to draw
conclusions about children. The absolute reduction averaged over
the whole illness can only be estimated from these data. The differ-
ence in the area under the survival curves of sore throat symptoms
for those treated with placebo as opposed to antibiotic is about 16
hours for the first week.
Estimates of the number of people with sore throat who must be
treated to resolve the symptoms of one by day three (the number
needed to treat to benefit (NNTB)) is about 3.7 for those with
positive throat swabs for Streptococcus. It is 6.5 for those with a
negative swab and 14.4 for those in whom no swab has been taken.
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The last result is difficult to understand. Intuitively one would
expect theNNTB value to lie between both the swab-negative and
swab-positive results. Perhaps participants with less severe throat
infections were recruited into the three studies in which swabs
were not taken.
Antibiotics are effective at reducing the relative complication rate
of people suffering sore throat. However, the relative benefit ex-
aggerates the absolute benefit because complication rates are low
and the illness is short-lived. Interpretation of these data is aided
by estimating the absolute benefit, which we attempt below.
In these trials, conducted mostly in the 1950s, for every 100 par-
ticipants treated with antibiotics rather than placebo, there was
one fewer case of acute rheumatic fever, two fewer cases of acute
otitis media and three fewer cases of quinsy. These figures need
to be adapted to current circumstances and individuals. For ex-
ample, the complication rate of acute otitis media among those
with sore throats before 1975 was 3%. A NNTB of about 50 to
prevent one case of acute otitis media can be estimated from the
data. After 1975, this complication rate fell to 0.7% and applying
the odds of reducing the complication with antibiotics from the
data table yields a NNTB of nearly 200 to prevent one case of
acute otitis media. Clinicians will have to exercise judgement in
applying these data to their patients.
In particular, in high-income countries (where absolute rates of
complications are lower) the NNTB will rise above a rate at which
it might be regarded as worthwhile to treat. In low-income coun-
tries where the absolute ratemay bemuch higher, the lowerNNTB
will mean antibiotics are more likely to be effective.
Adverse effects of treatment
We were unable to present the adverse effects of antibiotic
use because of inconsistencies in recording these symptoms. In
other studies these were principally diarrhea, rashes and thrush
(Venekamp 2013). Consideration of the side effects of antibiotics
would have been useful in further defining their risk-benefits.
Special risk groups
Acute rheumatic fever is common among people living in some
parts of the world (Australian Aborigines living in low socio-eco-
nomic conditions, for example) and antibiotics may be justified to
reduce the complication of acute rheumatic fever in these settings.
In other parts of the world the incidence of acute rheumatic fever
is so low (one estimate is that it took 12 General Practitioners’
working lifetimes to encounter one new case of acute rheumatic
fever in Western Scotland in the 1980s (Howie 1985)) that the
risks of serious complications arising from using antibiotics for
sore throat might be of the same order as that of acute rheumatic
fever.
Summary of main results
1. Symptoms
Throat soreness and fever were reduced by about half when us-
ing antibiotics. The greatest difference was seen at day three. The
number needed to treat to benefit (NNTB) to prevent one sore
throat at day three was less than six; at week one it was 21. Antibi-
otics were more effective against symptoms at day three and one
week if throat swabs were positive for Streptococcus compared to
negative throat swabs.
2. Non-suppurative complications
Antibiotics showed a trend for protecting against acute glomeru-
lonephritis but there were too few cases for the results to reach
statistical significance. Antibiotics reduced acute rheumatic fever
by more than two-thirds.
3. Suppurative complications
Antibiotics significantly reduced the incidence of acute otitis me-
dia by two-thirds, acute sinusitis by a half and quinsy by 85%
compared to those taking placebo.
Authors’ conclusions
Antibiotics confer relative benefits in the treatment of sore throat.
However, the absolute benefits are modest. Protecting sore throat
sufferers against suppurative and non-suppurative complications
in high-income countries requires treating many with antibiotics
for one to benefit. This NNTBmay be lower in low-income coun-
tries. Antibiotics shorten the duration of symptoms by about 16
hours overall.
Overall completeness and applicability of
evidence
Themajority of trials included in this review were conducted prior
to 1975, with only three trials published since 2000. The main
reason for this is that very few antibiotic trials conducted recently
include a placebo control arm. It is therefore unknown whether
changes in bacterial resistance and population immunity over time
may have altered the applicability of results.
Quality of the evidence
The quality of the evidence is considered to be moderate to high.
The greatest compromise to evidence quality arose from non-clar-
ity in treatment allocation procedures.
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Potential biases in the review process
Non-reporting of anti-pyretic use in a high number of studies may
have constituted a source of bias in the results. Publication bias
may also be considered a potential threat to the validity of results,
particularly for the earlier studies.
Agreements and disagreements with other
studies or reviews
A recent review analysing the risk-benefit profile of antimicrobial
prescribing for children concluded that antibiotics show little ben-
efit in preventing quinsy following sore throat (Keith 2010). A
clinical evidence review of antibiotic treatment for streptococcal
pharyngitis concluded that among patients with signs and symp-
toms of positive bacterial infection, a specific diagnosis should be
determined by performing either a throat culture or rapid anti-
gen-detection test, especially in children (Wessels 2011). Antibi-
otic treatment with penicillin or a first-generation cephalosporin
is then recommended in the case of positive bacteriologic assess-
ment.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Antibiotics have a beneficial effect on both suppurative and symp-
tom reduction.
The effect on symptoms is small, so that clinicians must judge
with individual cases whether it is clinically justifiable to employ
antibiotics to produce this effect. In other words their use should
be discretionary rather than either prohibited or mandatory. Since
90% of patients are symptom-free by one week (whether or not
treated with antibiotics), the absolute benefit of antibiotics at this
time and beyond is vanishingly small.
Acute rheumatic fever is common among people living in some
parts of the world (Australian Aborigines living in low socio-eco-
nomic conditions, for example) and antibiotics may be justified
to reduce the incidence of this complication in these settings. For
other settings where rheumatic fever is rare, there is a balance to
be made between modest symptom reduction and the hazards of
antimicrobial resistance.
Implications for research
More trials are needed in low-income countries, in socio-econom-
ically deprived sections of high-income countries and also in chil-
dren. Inhigh-income countries, better prognostic studies are called
for which can predict which patients may develop suppurative and
non-suppurative complications. This will help to further define
which patients benefit from antibiotics.
Studies which use patient-centred outcome measures compatible
with those presented here would be greatly beneficial, in terms of
easier comparison and analysis of results and ready inclusion into
future updates of this review.
Few trials have attempted to measure the severity of symptoms. If
antibiotics reduce the severity as well as the duration of symptoms,
their benefit will have been underestimated in this meta-analysis.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bennike 1951
Methods Open study, quasi-randomised
Participants 669 patients aged from less than 1 year to older than 50 years of age. Researchwas divided
into 3 studies: ordinary tonsillitis, “phlegmonous” tonsillitis and “ulcerative” tonsillitis.
Participants were excluded if they had a complication of tonsillitis on admission or if
they had previous antibiotic treatment for the present sore throat
Interventions Age-adjusted intramuscular penicillin twice daily for 6 days or no treatment as a control
condition
Outcomes Incidence of rheumatic fever, otitis media, quinsy, sinusitis and symptoms of sore throat
and headache
Notes No antipyretics were administered to the control group. The use of antipyretics to par-
ticipants in the treatment group was unstated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Participants allocated to alternate conditions on alter-
nate days
Allocation concealment (selection bias) High risk No concealment of allocation present
Blinding (performance bias and detection
bias)
All outcomes
High risk No blinding of participants or assessments
Incomplete outcome data (attrition bias)
All outcomes
Low risk
Selective reporting (reporting bias) Unclear risk No antipyretics were administered to the control
group. The use of antipyretics to participants in the
treatment group was unstated
Brink 1951
Methods Open study
Participants 395 young adult males recruited into United States Air Force
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Brink 1951 (Continued)
Interventions Intramuscular penicillin over 4 days, chlortetracycline for 3 days or no treatment as
control group
Outcomes Incidence of rheumatic fever, otitis media and symptoms of sore throat, fever and
headache
Notes No antipyretics were administered
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants randomised by Air Force serial number
Allocation concealment (selection bias) High risk
Blinding (performance bias and detection
bias)
All outcomes
High risk
Incomplete outcome data (attrition bias)
All outcomes
Low risk
Selective reporting (reporting bias) Low risk All relevant outcomes reported
Brumfitt 1957
Methods Open study
Participants 121 young adult men, aged 18 to 21 years, recruited into United States Air Force.
Participants were excluded from study if their temperature was below 99.3 degrees F, if
they had sore throat for more than 72 hours prior to presentation, or if they had some
other generalised illness
Interventions Intramuscular penicillin twice-daily for 4 days or no treatment as a control condition
Outcomes Incidence of rheumatic fever and symptoms of sore throat and fever
Notes Aspirin gargles were given 6-hourly.Whether participants were permitted to swallow the
aspirin was not documented
Risk of bias
Bias Authors’ judgement Support for judgement
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Brumfitt 1957 (Continued)
Random sequence generation (selection
bias)
Unclear risk Participants randomised by hospital bed number
Allocation concealment (selection bias) High risk
Blinding (performance bias and detection
bias)
All outcomes
High risk
Incomplete outcome data (attrition bias)
All outcomes
Low risk
Selective reporting (reporting bias) Low risk All relevant outcomes reported
Catanzaro 1954
Methods Single-blind, participants were unaware of treatment type, placebo-controlled trial. The
outcome of treatment was not determined blind
Participants 640 young adult males recruited into United States Air Force. Missing data were not
explained
Data from participants who produced a GABHS-negative throat swab were excluded.
Participants were excluded if they presented with a suppurative complication at the time
of admission
Interventions Intramuscular penicillin administered for 5 days, sulphonamide administered for 5 days
or no treatment as a control condition
Outcomes Incidence of rheumatic fever
Notes Antipyretic use was not documented
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants randomised by Air Force serial
number
Allocation concealment (selection bias) High risk
Blinding (performance bias and detection
bias)
All outcomes
Low risk
Incomplete outcome data (attrition bias)
All outcomes
Low risk
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Catanzaro 1954 (Continued)
Selective reporting (reporting bias) Unclear risk Antipyretic use was not documented
Chamovitz 1954
Methods Single-blind placebo study
Participants 366 young adult males recruited into United States Air Force. Participants were excluded
if they had previously developed rheumatic fever, had previous penicillin reaction or if
they had a suppurative complication at the time of admission
Interventions Intramuscular penicillin
Outcomes Incidence of rheumatic fever, otitis media and sinusitis
Notes Antipyretic use was not documented
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants randomised by Air Force serial number
Allocation concealment (selection bias) High risk
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Participants did not know treatment type they were receiv-
ing. The outcome of treatment was not determined blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk
Selective reporting (reporting bias) Unclear risk Antipyretic use was not documented
Chapple 1956
Methods Double-blind, placebo-controlled trial
Participants 308 participants older than 2 years. Data from 283 participants included in analyses
Interventions Age-adjusted oral penicillin, sulphadimidine or barium sulphate (placebo) administered
for 5 days
Outcomes Incidence of rheumatic fever, otitis media and symptom of sore throat
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Chapple 1956 (Continued)
Notes All groups received controlled doses of antipyretics twice daily for 3 days
Data from only 200 participants presenting with sore throat on day 1 included in sore
throat analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants randomised by random bottle dis-
pensing
Allocation concealment (selection bias) Low risk
Blinding (performance bias and detection
bias)
All outcomes
Low risk
Incomplete outcome data (attrition bias)
All outcomes
Low risk
Selective reporting (reporting bias) Low risk All relevant outcomes reported
Dagnelie 1996
Methods Randomised, double-blind, placebo-controlled trial of penicillin V on the course and
bacteriological response in patients with sore throat in general practice
Participants 239 patients aged 4 to 60, presenting with sore throat to 37 General Practices in the
Netherlands, who were clinically suspected of GABHS
Interventions Treatment with either penicillin V or placebo
Outcomes Resolution of sore throat, fever and return to daily activities (assessed by doctor and by
diary for 7 days)
Notes * Need raw data to make this study comparable to the meta-analysis, however data are
available for sore throat on day 3 and quinsy
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random sequence
Allocation concealment (selection bias) Low risk
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Dagnelie 1996 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind study design
Incomplete outcome data (attrition bias)
All outcomes
Low risk No attrition of participants
Selective reporting (reporting bias) Low risk All relevant outcomes reported
De Meyere 1992
Methods Double-blind, placebo-controlled trial
Participants 173 participants aged 5 to 50 years, from the Gent region of Belgium
Data were obtained from 173 participants on days 1 and 3
Data were obtained from 131 participants on days 2, 4, 5, 6 and 7
Participants excluded if they: produced a GABHS-negative throat swab, had a sore throat
for greater than 5 days, had a previous history of acute rheumatic fever, had an allergy
to beta-lactam antibiotics, had received any antibiotics within the past 14 days, were in
any high-risk situation as determined by the physician
Interventions Oral penicillin or oral placebo 3 times a day
Outcomes Symptom of sore throat
All data obtained, except from days 1 and 3, were self reported from a diary
Notes Antipyretics were used as required by participants. Use of antipyretics and other symp-
tom-relieving methods was documented in a diary
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation method not documented
Allocation concealment (selection bias) Low risk
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind study design
Incomplete outcome data (attrition bias)
All outcomes
Low risk
Selective reporting (reporting bias) Low risk All relevant outcomes reported
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Denny 1950
Methods Single-blind study. The outcome was determined blind on follow-up by physicians who
did not know what treatment type each participant had received
Participants 1602 young adult males recruited into United States Air Force
Interventions Intramuscular penicillin for 4 days or no treatment as a control group
Outcomes Incidence of rheumatic fever only
Notes Antipyretic use was not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants randomised by Air Force serial
number
Allocation concealment (selection bias) High risk
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Single blind study - assessment was con-
ducted by physicians who were unaware of
treatment condition
Incomplete outcome data (attrition bias)
All outcomes
Low risk
Selective reporting (reporting bias) Unclear risk Antipyretic use was not stated
Denny 1953
Methods Single-blind, randomised, placebo-controlled trial. Outcome determined blind by physi-
cians who did not know treatment type
Participants 103 young adultmales recruited in theUnited StatesAir Force. Participantswere excluded
if they had no exudate on their tonsils or larynx, if they had a leukocyte count of less
than 10,000; or if they had experienced symptoms of sore throat for more than 31 hours
Interventions Intramuscular penicillin daily for 5days, oral aureomycin or oral terramycin administered
every 6 hours for 3 days or oral lactose placebo for 3 days as a control condition
Outcomes Incidence of acute rheumatic fever, otitis media, quinsy, sinusitis and symptoms of sore
throat and headache
Notes No antipyretics were administered
Risk of bias
24Antibiotics for sore throat (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Denny 1953 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants were randomly allocated to
treatment groups by drawing a card from a
deck
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Single-blind study - assessment was con-
ducted by physicians who were unaware of
treatment condition
Incomplete outcome data (attrition bias)
All outcomes
Low risk
Selective reporting (reporting bias) Low risk All relevant outcomes reported
El-Daher 1991
Methods Double-blinded, randomised controlled trial
Participants 229 children with positive culture for GABHS
Interventions Early treatment with oral penicillin for 10 days versus oral placebo for 2 days followed
by oral penicillin for 8 days
Outcomes Symptoms of sore throat and headache on day 3
Notes Examination of participants was done on day 3 before administering penicillin to placebo
group
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk
Allocation concealment (selection bias) Low risk
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind study design
Incomplete outcome data (attrition bias)
All outcomes
Low risk No attrition of participants
Selective reporting (reporting bias) Low risk All relevant outcomes reported
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Howe 1997
Methods 22 GPs in one region of the UK recruited
Participants 154 patients aged 16 to 60 years presenting to their GP with sore throat and for whom
the GP would normally prescribe an antibiotic
Interventions Therapy with either penicillin V (250 mg 4 times a day), cefixime (200 mg daily) or
placebo
Outcomes Resolution of a composite “symptom score” with time; eradication of GABHS. A diary
was kept of symptom resolution over 7 days
Notes *Symptom results were bundled into a composite “symptom score”. The raw data on
sore throat, cough and fever resolution has been requested from the authors
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomisation scheme (performed
in blocks of 6)
Allocation concealment (selection bias) Low risk
Blinding (performance bias and detection
bias)
All outcomes
Low risk
Incomplete outcome data (attrition bias)
All outcomes
Low risk
Selective reporting (reporting bias) Low risk All relevant outcomes reported
Krober 1985
Methods Double-blind placebo trial
Participants 44 children presenting to a paediatric clinic. 26 of these participants yielded GABHS-
positive throat swabs
Participants were excluded if: the duration of symptoms was greater than 72 hours; they
had received oral antibiotics within the past 72 hours or intramuscular antibiotics within
the past 30 days; they had history of penicillin allergy; they had a rash suggestive of scarlet
fever; they had a concurrent infection that required antibiotics other than penicillin; or
if they had severe illness requiring immediate penicillin treatment
Participants who produced GABHS-negative throat swabs were excluded from the study
Interventions Oral penicillin or similar looking and tasting oral placebo for the control condition, 3
times a day for 3 days
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Krober 1985 (Continued)
Outcomes Symptom of fever
Notes Antipyretic use was not documented
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomised by table of random numbers
Allocation concealment (selection bias) Low risk
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind study design
Incomplete outcome data (attrition bias)
All outcomes
Low risk
Selective reporting (reporting bias) Unclear risk Antipyretic use was not documented
Landsman 1951
Methods Double-blind, randomised, placebo-controlled trial
Participants 95 participants who presented to general practice complaining of sore throat
Interventions Oral sulphonamide or similar looking and tasting oral placebo, for the control condition
Outcomes Incidence of sinusitis or quinsy or symptoms of sore throat or fever
Notes Antipyretic use was not documented
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised by randomnumbering of bot-
tles
Allocation concealment (selection bias) Low risk
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind study design
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Landsman 1951 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk
Selective reporting (reporting bias) Unclear risk Antipyretic use was not documented
Leelarasamee 2000
Methods Double-blind, randomised, placebo-controlled trial
Participants 1217 patients aged over 5 years presenting to 4 community-based medical centres with
complaints of fever or sore throat of less than 10 days duration
Interventions Participants were randomised to receive either amoxycillin or placebo for 7 days
Outcomes Duration of sore throat and fever. Incidence of complications and adverse reactions
Notes Antipyretics were given if deemed necessary by physicians
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random sequence
Allocation concealment (selection bias) Low risk
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind study design
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Some loss to follow-up occurred
Selective reporting (reporting bias) Low risk All relevant outcomes reported
Little 1997
Methods Unblinded randomised trial
Participants 716 patients aged 4 years and over, presenting to their GP with a sore throat, with an
abnormal physical finding localised to the throat (e.g. inflamed tonsils or pharynx, etc.)
Interventions Participants were randomised to 3 groups. Participants in the first group were given an
antibiotic for 10 days; those in the second group were given no prescription; and in
the third group were given an offer of antibiotic prescription if the symptoms were not
starting to settle after 3 days
28Antibiotics for sore throat (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Little 1997 (Continued)
Outcomes Main outcomes - duration of symptoms, satisfaction and compliance with and perceived
efficacy of antibiotics, time off school or work. Participants given a daily diary in which to
record symptoms and temperature. Participants who did not return diaries were followed
up over the phone
Notes Participants randomised, but neither participants nor doctors blinded to the therapy
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk
Allocation concealment (selection bias) High risk
Blinding (performance bias and detection
bias)
All outcomes
High risk No blinding of participants or assessors was performed
Incomplete outcome data (attrition bias)
All outcomes
Low risk No attrition of participants
Selective reporting (reporting bias) Low risk All relevant outcomes reported
MacDonald 1951
Methods Outcome determined blind
Participants 82 young adult males recruited into the United States Air Force
41 in treatment group; 41 in control group
Interventions Oral sulphatriad or identical oral lactose placebo, administered to the control condition,
taken every 4 hours
Outcomes Symptom of sore throat
Notes Antipyretics were administered to 1 participant in the treatment group and 2 participants
in the control group
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants randomised by Air Force serial number
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MacDonald 1951 (Continued)
Allocation concealment (selection bias) High risk
Blinding (performance bias and detection
bias)
All outcomes
Low risk Outcomes were determined blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk
Selective reporting (reporting bias) Low risk All relevant outcomes reported
Middleton 1988
Methods Multicentre, double-blind, randomised, placebo-controlled
Participants 178 participants aged 4 to 29 years with streptococcal pharyngitis. Participants had
symptom duration of less than 4 days. Results reported for 57 participants with severe
illness only
Interventions 8 individual doses of penicillin or placebo
Outcomes Symptoms of sore throat and fever
Notes Phone report after 48 hours used to measure outcome at day 3
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk
Allocation concealment (selection bias) Low risk
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind study design used
Incomplete outcome data (attrition bias)
All outcomes
Low risk No attrition of participants
Selective reporting (reporting bias) Low risk All relevant outcomes reported
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Nelson 1984
Methods An oral placebo was used to single-blind participants, however outcome was not deter-
mined blind
Participants 51 children aged 5 to 11 years. Sixteen participants were excluded because they did not
produce GABHS-positive throat swabs, leaving 35 participants. Children with history
of penicillin hypersensitivity were also excluded
Interventions Intramuscular penicillin or oral syrup placebo as a control group
Outcomes Symptoms of sore throat and fever
Notes No antipyretics were administered
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants randomised to conditions by
hospital number allocation
Allocation concealment (selection bias) High risk
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk An oral placebo was used to single-blind
participants.However outcomewas not de-
termined blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk
Selective reporting (reporting bias) Low risk All relevant outcomes reported
Petersen 1997
Methods Randomised placebo-controlled trial of participants’ culture-negative for GABHS
Participants 186 adults (aged 18 to 50) presenting to an ambulatory setting, whose chief complaint
was sore throat and whose GABHS culture was subsequently found to be negative
Interventions Treatment with either erythromycin (333 mg, 3 times daily) or placebo
Outcomes Main outcomes - time to improvement in sore throat, cough, activity level and sense
of well-being. Participants completed a daily questionnaire on the progress of outcome
measures. Follow-up visits were arranged 2 to 3 weeks after enrolment to repeat cultures,
collect diaries and assess compliance
Notes It is not clear how many participants kept diaries for the sore throat data in each group.
Authors excluded GABHS-positive patients (15 out of 212 initially randomised)
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Petersen 1997 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk
Allocation concealment (selection bias) Low risk
Blinding (performance bias and detection
bias)
All outcomes
Low risk
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk It is not clear how many participants kept
diaries for the sore throat data in each
group. Authors excluded GABHS-positive
participants (15 out of 212 initially ran-
domised)
Pichichero 1987
Methods Single-blind, randomised, placebo-controlled trial
Participants 114 GABHS-positive children aged 4 to 18 years. Children were excluded from the
study if: a throat swab was negative for GABHS; were allergic to penicillin; had received
penicillin in past 7 days; had another acute illness within 7 days, had a GABHS-positive
swab in past month, or had another concurrent infection that required antibiotics
Interventions Oral penicillin for 48 hours or an identical-looking and tasting oral placebo used for the
control condition
Outcomes Incidence of otitis media, quinsy or sinusitis
Notes Antipyretics administered 4-hourly
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random sequence
Allocation concealment (selection bias) Low risk
Blinding (performance bias and detection
bias)
All outcomes
Low risk Single-blind study design
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Pichichero 1987 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk No participant attrition
Selective reporting (reporting bias) Low risk All relevant outcomes reported
Siegel 1961
Methods Randomised controlled trial
Participants 1213 children aged 3 to 16 years. Suppurative complications occurring in participants
in the control condition were treated with sulphonamides. Participants were excluded if
they had a complication on admission
Interventions Intramuscular penicillin or no treatment for the controls
Outcomes Incidence of rheumatic fever
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants randomised by bed chart number
Allocation concealment (selection bias) High risk
Blinding (performance bias and detection
bias)
All outcomes
High risk
Incomplete outcome data (attrition bias)
All outcomes
Low risk
Selective reporting (reporting bias) Unclear risk Antipyretic use was not documented
Taylor 1977
Methods Double-blind, randomised, placebo-controlled trial
Participants 122 children aged 2 to 10 years. Children with positive Streptococcus throat swabs were
excluded
9 children were excluded during trial because of pre-existing suppurative complications
Interventions Oral amoxycillin, oral cotrimoxazole or an oral placebo was administered by parents 3
times a day for 5 days
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Taylor 1977 (Continued)
Outcomes Incidence of otitis media and sinusitis and symptoms of sore throat and fever
Notes Antipyretic use was not documented
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The method of randomisation to groups
was not documented
Allocation concealment (selection bias) Low risk
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind study design
Incomplete outcome data (attrition bias)
All outcomes
Low risk
Selective reporting (reporting bias) Unclear risk Antipyretic use was not documented
Wannamaker 1951
Methods Single-blind study. The intervention outcomes were determined by physicians who were
unaware of participant treatment allocation
Participants 1974 young adult males recruited into the United States Air Force
Interventions Intramuscular penicillin over 1 to 3 days or no treatment for the control condition
Outcomes Incidence of rheumatic fever
Notes Antipyretic use was not documented
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants randomised to groups by Air
Force serial number
Allocation concealment (selection bias) High risk
Blinding (performance bias and detection
bias)
All outcomes
Low risk Single-blind study design
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Wannamaker 1951 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk
Selective reporting (reporting bias) Unclear risk Antipyretic use was not documented
Whitfield 1981
Methods Double-blind, randomised, placebo-controlled trial
Participants Participants were people who presented to the General Practitioner with sore throat,
aged more than 10 years. 745 participants were commenced on the study. Only 528
returned questionnaires. Participants were excluded if the General Practitioner thought
the participant would demonstrate poor compliance; if they had previous reaction to
penicillin; or a previous episode of rheumatic fever or acute nephritis
Interventions Oral penicillin 4 times a day for 5 days or identical-looking and tasting oral lactose
placebo 4 times a day for 5 days
Outcomes Symptom of fever
Notes Antipyretic use was not documented
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised by pre-determined random
order
Allocation concealment (selection bias) Low risk
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind study design
Incomplete outcome data (attrition bias)
All outcomes
Low risk
Selective reporting (reporting bias) Unclear risk Antipyretic use was not documented
35Antibiotics for sore throat (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Zwart 2000
Methods Double-blind, randomised, placebo-controlled trial
Participants 561 participants aged 15 to 60 years presenting with sore throat of less than 7 days
duration
Interventions Penicillin V for 7 days, penicillin V for 3 days followed by 4 days of placebo or placebo
or 7 days
Outcomes Resolution of symptoms and recurrence of sore throat
Notes Author was contacted for data that could be used in the meta-analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random sequence
Allocation concealment (selection bias) Low risk
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind study design
Incomplete outcome data (attrition bias)
All outcomes
Low risk
Selective reporting (reporting bias) Low risk All relevant outcomes reported
Zwart 2003
Methods Double-blind, randomised, placebo-controlled trial
Participants 156 children aged 4 to 15 years presenting with sore throat of less than 7 days duration
with at least 2 of 4 Centor criteria
Interventions Penicillin V for 7 days, penicillin V for 3 days followed by 4 days of placebo or placebo
or 7 days
Outcomes Duration of symptoms of sore throat, occurrence of streptococcal sequelae
Notes Author was contacted for data that could be used in the meta-analysis
Risk of bias
Bias Authors’ judgement Support for judgement
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Zwart 2003 (Continued)
Random sequence generation (selection
bias)
Low risk Computer-generated random sequence
Allocation concealment (selection bias) Low risk
Blinding (performance bias and detection
bias)
All outcomes
Low risk
Incomplete outcome data (attrition bias)
All outcomes
Low risk
Selective reporting (reporting bias) Low risk All relevant outcomes reported
F: Farenheit
GABHS: group A beta haemolytic Streptococcus
GP: general practitioner
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Barwitz 1999 Participants were randomised to 2 GPs for subsequent treatment with different management protocols
Bass 1986 Study used a Likert scale to measure severity and duration of symptoms. No raw scores are available for entry
into meta-analysis
Bishop 1952 Non-randomised allocation to treatment groups. (Quote) “Where an exceptionally severe case fell in the control
group and it was felt unjustifiable to withhold specific treatment, the case was transferred to one of the other
groups and the next case was placed in the control group.” This bias was not quantified
Catanzaro 1958 Study compared sulphonamides with other antibiotics. No control condition was used
Cruickshank 1960 Study is another report of the data previously published by Brumfitt 1957
Dowell 2001 Cough was the main complaint for patients, not sore throat
Gerber 1985 Study compared 2 different regimens of penicillin. No placebo control group was used
Gerber 1989 Assessed 2 regimes of penicillin. No control group used
Ginsburg 1980 Study compared penicillin V with cefadroxil. No placebo control group was used
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(Continued)
Guthrie 1988 Study did not use control condition
Haverkorn 1971 Participants not treated with antibiotics given antipyretics. Participants receiving antibiotics received no an-
tipyretics. No control condition
Herz 1988 No participant-centred outcomes, except return visits for URIs
Poor randomisation - out of a series of 202, the first and last 50 were assigned to antibiotics, with the middle
102 assigned to control
Howie 1970 Illness was “cold or flu-like illness”, not acute pharyngitis (exclusively). Soreness of throat not an outcome
measure
Jensen 1991 Participants were not randomly allocated to treatment groups and were not blinded to treatment
Kapur 2011 No intervention was provided to participants. Study tracked natural course of illness only
Kolobukhina 2011 Study investigated the combination of Ingavirin (antiviral medication) with an antibacterial agent in adults
with viral respiratory infections. No comparison of antibiotics alone against placebo
Marlow 1989 Participant population highly selected (non-pregnant, negative rapid strep. test, negative throat culture, no
other infection present, not allergic to erythromycin, aged older than 12) and participant-centred outcomes
not compatible with those in this meta-analysis
Massell 1951 Study examined effect of penicillin on haemolytic streptococci infections in rheumatic patients only, without
randomisation to control condition. Infections that were not treated with penicillin for ’various reasons’ were
treated as controls. These reasons were not given
McDonald 1985 No data suitable for this meta-analysis were described although symptoms were recorded. The author was
approached for these data, but no reply was received
Merenstein 1974 No data on suppurative or non-suppurative complications
No data on day 3 for soreness of throat, fever or headache
Morris 1956 Study observed effect of sulfadiazine on prevention of rheumatic fever only. No control condition was used
Nasonova 1999 Study a controlled clinical trial without randomisation of participants
Pandraud 2002 Investigation of effect of fusafungine on chronic conditions of follicular pharyngitis. Not relevant for this review
Randolph 1985 No data on suppurative or non-suppurative complications
No data on day 3 or 7 for soreness of throat, fever or headache
Schalen 1985 Primary complaint hoarseness, not sore throat. No patient-centred outcomes apart from hoarseness
Schalen 1993 Patients presented for laryngitis and hoarseness, not pharyngitis
Schwartz 1981 Study compared 7 versus 10 days of treatment with penicillin. No control group was used
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(Continued)
Shevrygin 2000 Study was a clinical trial without a control condition
Shvartzman 1993 Study compared efficacy of amoxycillin against penicillin, no control condition was used
Stillerman 1986 Study compared penicillin with cephalosporins, no control group was used
Stromberg 1988 No placebo control group was used. Study compared different antibiotic regimens
Supajatura 2012 Antibiotics were not offered as an intervention. Study investigated the efficacy of Mangosteen spray against
placebo only
Todd 1984 Primary complaint not sore throat - purulent nasopharyngitis instead
Valkenburg 1971 Study did not involve any control measures. Data only given for participants not treated with antibiotics
GP: general practitioner
URIs: upper respiratory infections
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D A T A A N D A N A L Y S E S
Comparison 1. Antibiotics versus placebo for the treatment of sore throats: symptom of sore throat
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Symptom of sore throat on day 3 15 3621 Risk Ratio (M-H, Random, 95% CI) 0.68 [0.59, 0.79]
2 Symptom of sore throat on
day 3: blind versus unblinded
studies
15 3621 Risk Ratio (M-H, Random, 95% CI) 0.68 [0.59, 0.79]
2.1 Symptom of sore throat
on day 3: blinded studies
12 2662 Risk Ratio (M-H, Random, 95% CI) 0.65 [0.54, 0.78]
2.2 Symptom of sore throat
on day 3: unblinded studies
3 959 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.60, 1.05]
3 Symptom of sore throat on
day 3: antipyretics versus no
antipyretics
5 1137 Risk Ratio (M-H, Random, 95% CI) 0.58 [0.48, 0.70]
3.1 Symptom of sore throat on
day 3: antipyretics administered
3 455 Risk Ratio (M-H, Random, 95% CI) 0.52 [0.33, 0.81]
3.2 Symptom of sore throat
on day 3: no antipyretics
administered
2 682 Risk Ratio (M-H, Random, 95% CI) 0.62 [0.55, 0.70]
4 Symptom of sore throat on
day 3: GABHS-positive
throat swab, negative swab,
untested/inseparable
15 3600 Risk Ratio (M-H, Random, 95% CI) 0.68 [0.59, 0.78]
4.1 Symptom of sore throat
on day 3: GABHS-positive
throat swab
11 1839 Risk Ratio (M-H, Random, 95% CI) 0.58 [0.48, 0.71]
4.2 Symptom of sore throat
on day 3: GABHS-negative
throat swab
6 736 Risk Ratio (M-H, Random, 95% CI) 0.78 [0.63, 0.97]
4.3 Symptom of sore
throat on day 3: untested for
GABHS culture or combined
inseparable data
3 1025 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.80, 1.00]
5 Symptom of sore throat at one
week (6 to 8 days)
13 2974 Risk Ratio (M-H, Random, 95% CI) 0.49 [0.32, 0.76]
6 Symptom of sore throat at one
week (6 to 8 days): blind versus
unblinded studies
13 2944 Risk Ratio (M-H, Random, 95% CI) 0.57 [0.38, 0.86]
6.1 Symptom of sore throat at
1 week (6 to 8 days): blinded
studies
9 1616 Risk Ratio (M-H, Random, 95% CI) 0.62 [0.38, 1.03]
6.2 Symptom of sore throat at
1 week (6 to 8 days): unblinded
studies
4 1328 Risk Ratio (M-H, Random, 95% CI) 0.30 [0.08, 1.15]
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7 Symptom of sore throat at
one week (6 to 8 days):
GABHS-positive throat swab,
GABHS-negative swab
12 2524 Risk Ratio (M-H, Random, 95% CI) 0.48 [0.29, 0.80]
7.1 Symptom of sore throat at
1 week (6 to 8 days): GABHS-
positive throat swab
7 1117 Risk Ratio (M-H, Random, 95% CI) 0.29 [0.12, 0.70]
7.2 Symptom of sore throat at
1 week (6 to 8 days): GABHS-
negative throat swab
5 541 Risk Ratio (M-H, Random, 95% CI) 0.73 [0.50, 1.07]
7.3 Symptom of sore throat at
1 week (6 to 8 days): GABHS
untested
3 866 Risk Ratio (M-H, Random, 95% CI) 0.35 [0.03, 4.47]
Comparison 2. Antibiotics versus control for the treatment of sore throat: symptom of fever
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Symptom of fever on day 3 7 1334 Risk Ratio (M-H, Random, 95% CI) 0.71 [0.45, 1.10]
2 Symptom of fever on day 3:
blinded versus unblinded
studies
7 1334 Risk Ratio (M-H, Random, 95% CI) 0.71 [0.45, 1.10]
2.1 Symptom of fever on day
3: blinded studies.
4 703 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.54, 1.23]
2.2 Symptom of fever on day
3: unblinded studies.
3 631 Risk Ratio (M-H, Random, 95% CI) 0.65 [0.31, 1.37]
3 Symptom of fever on day 3:
children compared with adults
4 657 Risk Ratio (M-H, Random, 95% CI) 0.51 [0.18, 1.46]
3.1 Symptom of fever on day
3: children
2 61 Risk Ratio (M-H, Random, 95% CI) 1.27 [0.76, 2.13]
3.2 Symptom of fever on day
3: adults
2 596 Risk Ratio (M-H, Random, 95% CI) 0.29 [0.06, 1.51]
4 Symptom of fever at 1 week (6
to 8 days)
3 777 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 3. Antibiotics versus control for the treatment of sore throat: symptom of headache
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Symptom of headache on day 3 3 911 Risk Ratio (M-H, Random, 95% CI) 0.44 [0.27, 0.71]
2 Symptom of headache on day
3: blinded versus unblinded
studies
3 911 Risk Ratio (M-H, Random, 95% CI) 0.44 [0.27, 0.71]
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2.1 Symptom headache on
day 3: blinded studies
2 436 Risk Ratio (M-H, Random, 95% CI) 0.33 [0.09, 1.20]
2.2 Symptom of headache on
day 3: unblinded studies
1 475 Risk Ratio (M-H, Random, 95% CI) 0.55 [0.41, 0.72]
Comparison 4. Antibiotics versus placebo for the treatment of sore throat: incidence of complications
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incidence of acute rheumatic
fever within 2 months.
Rheumatic fever defined by
clinical diagnosis
16 10101 Risk Ratio (M-H, Random, 95% CI) 0.27 [0.12, 0.60]
2 Incidence of acute rheumatic
fever within 2 months.
Penicillin versus placebo
14 8175 Risk Ratio (M-H, Random, 95% CI) 0.27 [0.14, 0.50]
3 Incidence of acute rheumatic
fever within 2 months: early
(pre-1975) versus late studies
(post-1975)
16 10101 Risk Ratio (M-H, Random, 95% CI) 0.27 [0.12, 0.60]
3.1 Incidence of acute
rheumatic fever within 2
months: early (pre-1975)
studies
10 7617 Risk Ratio (M-H, Random, 95% CI) 0.27 [0.12, 0.60]
3.2 Incidence of acute
rheumatic fever within 2
months: late (post-1975)
studies
6 2484 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4 Incidence of otitis media within
14 days. Otitis media defined
by clinical diagnosis
11 3760 Risk Ratio (M-H, Random, 95% CI) 0.30 [0.15, 0.58]
5 Incidence of otitis media within
14 days: early (pre-1975) versus
late studies (post-1975)
11 3760 Risk Ratio (M-H, Random, 95% CI) 0.30 [0.15, 0.58]
5.1 Incidence of otitis media
within 14 days: early (pre-
1975) studies
5 1837 Risk Ratio (M-H, Random, 95% CI) 0.30 [0.15, 0.62]
5.2 Incidence of otitis media
within 14 days: late (post-
1975) studies
6 1923 Risk Ratio (M-H, Random, 95% CI) 0.28 [0.03, 2.74]
6 Incidence of sinusitis within
14 days. Sinusitis defined by
clinical diagnosis
8 2387 Risk Ratio (M-H, Random, 95% CI) 0.48 [0.08, 2.76]
7 Incidence of quinsy within 2
months. Quinsy defined by
clinical diagnosis
8 2433 Risk Ratio (M-H, Random, 95% CI) 0.15 [0.05, 0.47]
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8 Incidence of acute
glomerulonephritis
within 1 month. Acute
glomerulonephritis defined by
clinical diagnosis
10 5147 Risk Ratio (M-H, Random, 95% CI) 0.22 [0.02, 2.08]
Analysis 1.1. Comparison 1 Antibiotics versus placebo for the treatment of sore throats: symptom of sore
throat, Outcome 1 Symptom of sore throat on day 3.
Review: Antibiotics for sore throat
Comparison: 1 Antibiotics versus placebo for the treatment of sore throats: symptom of sore throat
Outcome: 1 Symptom of sore throat on day 3
Study or subgroup Antibiotics Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Brink 1951 119/277 129/198 8.5 % 0.66 [ 0.56, 0.78 ]
Brumfitt 1957 21/42 26/40 5.9 % 0.77 [ 0.53, 1.12 ]
Chapple 1956 40/135 37/65 6.4 % 0.52 [ 0.37, 0.73 ]
Dagnelie 1996 36/117 57/117 6.5 % 0.63 [ 0.45, 0.88 ]
De Meyere 1992 18/82 59/91 5.2 % 0.34 [ 0.22, 0.52 ]
Denny 1953 89/157 48/50 8.7 % 0.59 [ 0.51, 0.68 ]
El-Daher 1991 42/111 106/118 7.6 % 0.42 [ 0.33, 0.54 ]
Landsman 1951 6/52 7/43 1.7 % 0.71 [ 0.26, 1.95 ]
Little 1997 135/215 122/187 8.8 % 0.96 [ 0.83, 1.11 ]
MacDonald 1951 18/41 27/41 5.5 % 0.67 [ 0.44, 1.00 ]
Middleton 1988 2/34 5/23 0.8 % 0.27 [ 0.06, 1.28 ]
Petersen 1997 60/89 74/90 8.5 % 0.82 [ 0.69, 0.98 ]
Whitfield 1981 129/256 165/272 8.7 % 0.83 [ 0.71, 0.97 ]
Zwart 2000 215/358 131/164 9.1 % 0.75 [ 0.67, 0.84 ]
Zwart 2003 79/100 38/56 8.1 % 1.16 [ 0.95, 1.43 ]
Total (95% CI) 2066 1555 100.0 % 0.68 [ 0.59, 0.79 ]
Total events: 1009 (Antibiotics), 1031 (Placebo)
Heterogeneity: Tau2 = 0.06; Chi2 = 85.89, df = 14 (P<0.00001); I2 =84%
Test for overall effect: Z = 5.03 (P < 0.00001)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours antibiotics Favours placebo
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Analysis 1.2. Comparison 1 Antibiotics versus placebo for the treatment of sore throats: symptom of sore
throat, Outcome 2 Symptom of sore throat on day 3: blind versus unblinded studies.
Review: Antibiotics for sore throat
Comparison: 1 Antibiotics versus placebo for the treatment of sore throats: symptom of sore throat
Outcome: 2 Symptom of sore throat on day 3: blind versus unblinded studies
Study or subgroup Antibiotics Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Symptom of sore throat on day 3: blinded studies
Chapple 1956 40/135 37/65 6.4 % 0.52 [ 0.37, 0.73 ]
Dagnelie 1996 36/117 57/117 6.5 % 0.63 [ 0.45, 0.88 ]
De Meyere 1992 18/82 59/91 5.2 % 0.34 [ 0.22, 0.52 ]
Denny 1953 89/157 48/50 8.7 % 0.59 [ 0.51, 0.68 ]
El-Daher 1991 42/111 106/118 7.6 % 0.42 [ 0.33, 0.54 ]
Landsman 1951 6/52 7/43 1.7 % 0.71 [ 0.26, 1.95 ]
MacDonald 1951 18/41 27/41 5.5 % 0.67 [ 0.44, 1.00 ]
Middleton 1988 2/34 5/23 0.8 % 0.27 [ 0.06, 1.28 ]
Petersen 1997 60/89 74/90 8.5 % 0.82 [ 0.69, 0.98 ]
Whitfield 1981 129/256 165/272 8.7 % 0.83 [ 0.71, 0.97 ]
Zwart 2000 215/358 131/164 9.1 % 0.75 [ 0.67, 0.84 ]
Zwart 2003 79/100 38/56 8.1 % 1.16 [ 0.95, 1.43 ]
Subtotal (95% CI) 1532 1130 76.8 % 0.65 [ 0.54, 0.78 ]
Total events: 734 (Antibiotics), 754 (Placebo)
Heterogeneity: Tau2 = 0.07; Chi2 = 70.93, df = 11 (P<0.00001); I2 =84%
Test for overall effect: Z = 4.67 (P < 0.00001)
2 Symptom of sore throat on day 3: unblinded studies
Brink 1951 119/277 129/198 8.5 % 0.66 [ 0.56, 0.78 ]
Brumfitt 1957 21/42 26/40 5.9 % 0.77 [ 0.53, 1.12 ]
Little 1997 135/215 122/187 8.8 % 0.96 [ 0.83, 1.11 ]
Subtotal (95% CI) 534 425 23.2 % 0.79 [ 0.60, 1.05 ]
Total events: 275 (Antibiotics), 277 (Placebo)
0.05 0.2 1 5 20
Favours antibiotics Favours placebo
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(. . . Continued)
Study or subgroup Antibiotics Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Heterogeneity: Tau2 = 0.05; Chi2 = 11.17, df = 2 (P = 0.004); I2 =82%
Test for overall effect: Z = 1.62 (P = 0.11)
Total (95% CI) 2066 1555 100.0 % 0.68 [ 0.59, 0.79 ]
Total events: 1009 (Antibiotics), 1031 (Placebo)
Heterogeneity: Tau2 = 0.06; Chi2 = 85.89, df = 14 (P<0.00001); I2 =84%
Test for overall effect: Z = 5.03 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.31, df = 1 (P = 0.25), I2 =23%
0.05 0.2 1 5 20
Favours antibiotics Favours placebo
Analysis 1.3. Comparison 1 Antibiotics versus placebo for the treatment of sore throats: symptom of sore
throat, Outcome 3 Symptom of sore throat on day 3: antipyretics versus no antipyretics.
Review: Antibiotics for sore throat
Comparison: 1 Antibiotics versus placebo for the treatment of sore throats: symptom of sore throat
Outcome: 3 Symptom of sore throat on day 3: antipyretics versus no antipyretics
Study or subgroup Antibiotics Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Symptom of sore throat on day 3: antipyretics administered
Brumfitt 1957 21/42 26/40 14.4 % 0.77 [ 0.53, 1.12 ]
Chapple 1956 40/135 37/65 16.6 % 0.52 [ 0.37, 0.73 ]
De Meyere 1992 18/82 59/91 12.1 % 0.34 [ 0.22, 0.52 ]
Subtotal (95% CI) 259 196 43.1 % 0.52 [ 0.33, 0.81 ]
Total events: 79 (Antibiotics), 122 (Placebo)
Heterogeneity: Tau2 = 0.12; Chi2 = 8.26, df = 2 (P = 0.02); I2 =76%
Test for overall effect: Z = 2.87 (P = 0.0041)
2 Symptom of sore throat on day 3: no antipyretics administered
Brink 1951 119/277 129/198 27.6 % 0.66 [ 0.56, 0.78 ]
Denny 1953 89/157 48/50 29.2 % 0.59 [ 0.51, 0.68 ]
0.05 0.2 1 5 20
Favours antibiotics Favours placebo
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Study or subgroup Antibiotics Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 434 248 56.9 % 0.62 [ 0.55, 0.70 ]
Total events: 208 (Antibiotics), 177 (Placebo)
Heterogeneity: Tau2 = 0.00; Chi2 = 1.17, df = 1 (P = 0.28); I2 =14%
Test for overall effect: Z = 7.76 (P < 0.00001)
Total (95% CI) 693 444 100.0 % 0.58 [ 0.48, 0.70 ]
Total events: 287 (Antibiotics), 299 (Placebo)
Heterogeneity: Tau2 = 0.03; Chi2 = 10.52, df = 4 (P = 0.03); I2 =62%
Test for overall effect: Z = 5.76 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.57, df = 1 (P = 0.45), I2 =0.0%
0.05 0.2 1 5 20
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Analysis 1.4. Comparison 1 Antibiotics versus placebo for the treatment of sore throats: symptom of sore
throat, Outcome 4 Symptom of sore throat on day 3: GABHS-positive throat swab, negative swab,
untested/inseparable.
Review: Antibiotics for sore throat
Comparison: 1 Antibiotics versus placebo for the treatment of sore throats: symptom of sore throat
Outcome: 4 Symptom of sore throat on day 3: GABHS-positive throat swab, negative swab, untested/inseparable
Study or subgroup Antibiotics Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Symptom of sore throat on day 3: GABHS-positive throat swab
Brink 1951 119/277 129/198 6.9 % 0.66 [ 0.56, 0.78 ]
Brumfitt 1957 21/42 26/40 4.9 % 0.77 [ 0.53, 1.12 ]
Chapple 1956 13/68 22/41 3.4 % 0.36 [ 0.20, 0.63 ]
Dagnelie 1996 13/55 36/55 3.8 % 0.36 [ 0.22, 0.60 ]
De Meyere 1992 18/82 59/91 4.4 % 0.34 [ 0.22, 0.52 ]
Denny 1953 89/157 48/50 7.0 % 0.59 [ 0.51, 0.68 ]
El-Daher 1991 42/111 106/118 6.2 % 0.42 [ 0.33, 0.54 ]
MacDonald 1951 13/26 17/24 4.2 % 0.71 [ 0.44, 1.12 ]
Middleton 1988 2/24 5/23 0.8 % 0.38 [ 0.08, 1.78 ]
Zwart 2000 102/178 68/83 6.9 % 0.70 [ 0.59, 0.82 ]
Zwart 2003 39/53 28/43 5.9 % 1.13 [ 0.86, 1.48 ]
Subtotal (95% CI) 1073 766 54.5 % 0.58 [ 0.48, 0.71 ]
Total events: 471 (Antibiotics), 544 (Placebo)
Heterogeneity: Tau2 = 0.08; Chi2 = 51.31, df = 10 (P<0.00001); I2 =81%
Test for overall effect: Z = 5.34 (P < 0.00001)
2 Symptom of sore throat on day 3: GABHS-negative throat swab
Chapple 1956 13/67 16/26 3.4 % 0.32 [ 0.18, 0.56 ]
Dagnelie 1996 31/60 29/51 5.3 % 0.91 [ 0.65, 1.28 ]
MacDonald 1951 5/15 10/17 2.1 % 0.57 [ 0.25, 1.29 ]
Petersen 1997 60/89 74/90 6.8 % 0.82 [ 0.69, 0.98 ]
Zwart 2000 113/180 63/81 6.9 % 0.81 [ 0.69, 0.95 ]
Zwart 2003 40/47 10/13 5.5 % 1.11 [ 0.80, 1.52 ]
Subtotal (95% CI) 458 278 30.0 % 0.78 [ 0.63, 0.97 ]
Total events: 262 (Antibiotics), 202 (Placebo)
Heterogeneity: Tau2 = 0.04; Chi2 = 15.65, df = 5 (P = 0.01); I2 =68%
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Study or subgroup Antibiotics Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Test for overall effect: Z = 2.20 (P = 0.028)
3 Symptom of sore throat on day 3: untested for GABHS culture or combined inseparable data
Landsman 1951 6/52 7/43 1.5 % 0.71 [ 0.26, 1.95 ]
Little 1997 135/215 122/187 7.0 % 0.96 [ 0.83, 1.11 ]
Whitfield 1981 129/256 165/272 7.0 % 0.83 [ 0.71, 0.97 ]
Subtotal (95% CI) 523 502 15.6 % 0.89 [ 0.80, 1.00 ]
Total events: 270 (Antibiotics), 294 (Placebo)
Heterogeneity: Tau2 = 0.00; Chi2 = 2.08, df = 2 (P = 0.35); I2 =4%
Test for overall effect: Z = 1.98 (P = 0.048)
Total (95% CI) 2054 1546 100.0 % 0.68 [ 0.59, 0.78 ]
Total events: 1003 (Antibiotics), 1040 (Placebo)
Heterogeneity: Tau2 = 0.07; Chi2 = 103.16, df = 19 (P<0.00001); I2 =82%
Test for overall effect: Z = 5.46 (P < 0.00001)
Test for subgroup differences: Chi2 = 13.85, df = 2 (P = 0.00), I2 =86%
0.05 0.2 1 5 20
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Analysis 1.5. Comparison 1 Antibiotics versus placebo for the treatment of sore throats: symptom of sore
throat, Outcome 5 Symptom of sore throat at one week (6 to 8 days).
Review: Antibiotics for sore throat
Comparison: 1 Antibiotics versus placebo for the treatment of sore throats: symptom of sore throat
Outcome: 5 Symptom of sore throat at one week (6 to 8 days)
Study or subgroup Antibiotics Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bennike 1951 0/100 7/99 2.0 % 0.07 [ 0.00, 1.14 ]
Brink 1951 4/277 15/198 8.2 % 0.19 [ 0.06, 0.57 ]
Brumfitt 1957 0/42 2/40 1.9 % 0.19 [ 0.01, 3.85 ]
Dagnelie 1996 3/51 15/51 7.5 % 0.20 [ 0.06, 0.65 ]
De Meyere 1992 3/61 10/70 7.1 % 0.34 [ 0.10, 1.19 ]
Denny 1953 6/157 16/50 9.9 % 0.12 [ 0.05, 0.29 ]
Landsman 1951 0/52 0/43 Not estimable
Little 1997 66/388 35/184 14.9 % 0.89 [ 0.62, 1.30 ]
MacDonald 1951 0/41 1/41 1.7 % 0.33 [ 0.01, 7.95 ]
Petersen 1997 21/89 32/90 14.0 % 0.66 [ 0.42, 1.06 ]
Taylor 1977 6/129 3/59 6.4 % 0.91 [ 0.24, 3.53 ]
Zwart 2000 117/352 63/154 15.9 % 0.81 [ 0.64, 1.03 ]
Zwart 2003 20/100 7/56 10.7 % 1.60 [ 0.72, 3.55 ]
Total (95% CI) 1839 1135 100.0 % 0.49 [ 0.32, 0.76 ]
Total events: 246 (Antibiotics), 206 (Placebo)
Heterogeneity: Tau2 = 0.30; Chi2 = 38.59, df = 11 (P = 0.00006); I2 =71%
Test for overall effect: Z = 3.19 (P = 0.0014)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 Antibiotics versus placebo for the treatment of sore throats: symptom of sore
throat, Outcome 6 Symptom of sore throat at one week (6 to 8 days): blind versus unblinded studies.
Review: Antibiotics for sore throat
Comparison: 1 Antibiotics versus placebo for the treatment of sore throats: symptom of sore throat
Outcome: 6 Symptom of sore throat at one week (6 to 8 days): blind versus unblinded studies
Study or subgroup Antibiotics Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Symptom of sore throat at 1 week (6 to 8 days): blinded studies
Dagnelie 1996 4/47 3/35 5.7 % 0.99 [ 0.24, 4.16 ]
De Meyere 1992 3/51 10/70 6.8 % 0.41 [ 0.12, 1.42 ]
Denny 1953 6/157 16/50 9.9 % 0.12 [ 0.05, 0.29 ]
Landsman 1951 0/52 0/43 Not estimable
MacDonald 1951 0/41 1/41 1.5 % 0.33 [ 0.01, 7.95 ]
Petersen 1997 21/89 32/90 14.7 % 0.66 [ 0.42, 1.06 ]
Taylor 1977 6/129 3/59 6.1 % 0.91 [ 0.24, 3.53 ]
Zwart 2000 117/352 63/154 17.1 % 0.81 [ 0.64, 1.03 ]
Zwart 2003 20/100 7/56 10.8 % 1.60 [ 0.72, 3.55 ]
Subtotal (95% CI) 1018 598 72.6 % 0.62 [ 0.38, 1.03 ]
Total events: 177 (Antibiotics), 135 (Placebo)
Heterogeneity: Tau2 = 0.28; Chi2 = 22.27, df = 7 (P = 0.002); I2 =69%
Test for overall effect: Z = 1.83 (P = 0.068)
2 Symptom of sore throat at 1 week (6 to 8 days): unblinded studies
Bennike 1951 0/100 7/99 1.9 % 0.07 [ 0.00, 1.14 ]
Brink 1951 4/277 15/198 8.0 % 0.19 [ 0.06, 0.57 ]
Brumfitt 1957 0/42 2/40 1.7 % 0.19 [ 0.01, 3.85 ]
Little 1997 66/388 35/184 15.8 % 0.89 [ 0.62, 1.30 ]
Subtotal (95% CI) 807 521 27.4 % 0.30 [ 0.08, 1.15 ]
Total events: 70 (Antibiotics), 59 (Placebo)
Heterogeneity: Tau2 = 1.10; Chi2 = 11.19, df = 3 (P = 0.01); I2 =73%
Test for overall effect: Z = 1.76 (P = 0.079)
Total (95% CI) 1825 1119 100.0 % 0.57 [ 0.38, 0.86 ]
Total events: 247 (Antibiotics), 194 (Placebo)
Heterogeneity: Tau2 = 0.24; Chi2 = 33.28, df = 11 (P = 0.00047); I2 =67%
Test for overall effect: Z = 2.71 (P = 0.0068)
Test for subgroup differences: Chi2 = 0.98, df = 1 (P = 0.32), I2 =0.0%
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Analysis 1.7. Comparison 1 Antibiotics versus placebo for the treatment of sore throats: symptom of sore
throat, Outcome 7 Symptom of sore throat at one week (6 to 8 days): GABHS-positive throat swab, GABHS-
negative swab.
Review: Antibiotics for sore throat
Comparison: 1 Antibiotics versus placebo for the treatment of sore throats: symptom of sore throat
Outcome: 7 Symptom of sore throat at one week (6 to 8 days): GABHS-positive throat swab, GABHS-negative swab
Study or subgroup Antibiotics Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Symptom of sore throat at 1 week (6 to 8 days): GABHS-positive throat swab
Brink 1951 4/277 15/198 9.1 % 0.19 [ 0.06, 0.57 ]
Brumfitt 1957 0/42 2/40 2.4 % 0.19 [ 0.01, 3.85 ]
Dagnelie 1996 1/34 10/42 4.5 % 0.12 [ 0.02, 0.92 ]
De Meyere 1992 3/61 10/70 8.0 % 0.34 [ 0.10, 1.19 ]
Denny 1953 6/157 16/50 10.6 % 0.12 [ 0.05, 0.29 ]
MacDonald 1951 0/26 1/24 2.2 % 0.31 [ 0.01, 7.23 ]
Zwart 2003 8/53 3/43 7.9 % 2.16 [ 0.61, 7.66 ]
Subtotal (95% CI) 650 467 44.6 % 0.29 [ 0.12, 0.70 ]
Total events: 22 (Antibiotics), 57 (Placebo)
Heterogeneity: Tau2 = 0.77; Chi2 = 14.90, df = 6 (P = 0.02); I2 =60%
Test for overall effect: Z = 2.74 (P = 0.0061)
2 Symptom of sore throat at 1 week (6 to 8 days): GABHS-negative throat swab
Dagnelie 1996 3/35 4/47 6.9 % 1.01 [ 0.24, 4.22 ]
MacDonald 1951 0/15 0/17 Not estimable
Petersen 1997 21/89 32/90 13.9 % 0.66 [ 0.42, 1.06 ]
Taylor 1977 6/129 3/59 7.4 % 0.91 [ 0.24, 3.53 ]
Zwart 2003 12/47 4/13 10.1 % 0.83 [ 0.32, 2.15 ]
Subtotal (95% CI) 315 226 38.2 % 0.73 [ 0.50, 1.07 ]
Total events: 42 (Antibiotics), 43 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.53, df = 3 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 1.61 (P = 0.11)
3 Symptom of sore throat at 1 week (6 to 8 days): GABHS untested
Bennike 1951 0/100 7/99 2.6 % 0.07 [ 0.00, 1.14 ]
Landsman 1951 0/52 0/43 Not estimable
Little 1997 66/388 35/184 14.5 % 0.89 [ 0.62, 1.30 ]
Subtotal (95% CI) 540 326 17.1 % 0.35 [ 0.03, 4.47 ]
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(. . . Continued)
Study or subgroup Antibiotics Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 66 (Antibiotics), 42 (Placebo)
Heterogeneity: Tau2 = 2.58; Chi2 = 3.40, df = 1 (P = 0.07); I2 =71%
Test for overall effect: Z = 0.81 (P = 0.42)
Total (95% CI) 1505 1019 100.0 % 0.48 [ 0.29, 0.80 ]
Total events: 130 (Antibiotics), 142 (Placebo)
Heterogeneity: Tau2 = 0.42; Chi2 = 33.79, df = 12 (P = 0.00073); I2 =64%
Test for overall effect: Z = 2.84 (P = 0.0045)
Test for subgroup differences: Chi2 = 3.72, df = 2 (P = 0.16), I2 =46%
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Analysis 2.1. Comparison 2 Antibiotics versus control for the treatment of sore throat: symptom of fever,
Outcome 1 Symptom of fever on day 3.
Review: Antibiotics for sore throat
Comparison: 2 Antibiotics versus control for the treatment of sore throat: symptom of fever
Outcome: 1 Symptom of fever on day 3
Study or subgroup Antibiotics Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Brink 1951 34/277 40/198 27.4 % 0.61 [ 0.40, 0.92 ]
Brumfitt 1957 6/62 19/59 15.6 % 0.30 [ 0.13, 0.70 ]
Krober 1985 0/15 0/11 Not estimable
Landsman 1951 1/52 3/43 3.5 % 0.28 [ 0.03, 2.56 ]
Middleton 1988 1/33 0/21 1.9 % 1.94 [ 0.08, 45.54 ]
Nelson 1984 12/17 10/18 24.3 % 1.27 [ 0.76, 2.13 ]
Whitfield 1981 33/256 42/272 27.3 % 0.83 [ 0.55, 1.27 ]
Total (95% CI) 712 622 100.0 % 0.71 [ 0.45, 1.10 ]
Total events: 87 (Antibiotics), 114 (Placebo)
Heterogeneity: Tau2 = 0.14; Chi2 = 11.38, df = 5 (P = 0.04); I2 =56%
Test for overall effect: Z = 1.55 (P = 0.12)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 Antibiotics versus control for the treatment of sore throat: symptom of fever,
Outcome 2 Symptom of fever on day 3: blinded versus unblinded studies.
Review: Antibiotics for sore throat
Comparison: 2 Antibiotics versus control for the treatment of sore throat: symptom of fever
Outcome: 2 Symptom of fever on day 3: blinded versus unblinded studies
Study or subgroup Antibiotics Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Symptom of fever on day 3: blinded studies.
Krober 1985 0/15 0/11 Not estimable
Landsman 1951 1/52 3/43 3.5 % 0.28 [ 0.03, 2.56 ]
Middleton 1988 1/33 0/21 1.9 % 1.94 [ 0.08, 45.54 ]
Whitfield 1981 33/256 42/272 27.3 % 0.83 [ 0.55, 1.27 ]
Subtotal (95% CI) 356 347 32.7 % 0.82 [ 0.54, 1.23 ]
Total events: 35 (Antibiotics), 45 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.21, df = 2 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 0.97 (P = 0.33)
2 Symptom of fever on day 3: unblinded studies.
Brink 1951 34/277 40/198 27.4 % 0.61 [ 0.40, 0.92 ]
Brumfitt 1957 6/62 19/59 15.6 % 0.30 [ 0.13, 0.70 ]
Nelson 1984 12/17 10/18 24.3 % 1.27 [ 0.76, 2.13 ]
Subtotal (95% CI) 356 275 67.3 % 0.65 [ 0.31, 1.37 ]
Total events: 52 (Antibiotics), 69 (Placebo)
Heterogeneity: Tau2 = 0.34; Chi2 = 10.42, df = 2 (P = 0.01); I2 =81%
Test for overall effect: Z = 1.13 (P = 0.26)
Total (95% CI) 712 622 100.0 % 0.71 [ 0.45, 1.10 ]
Total events: 87 (Antibiotics), 114 (Placebo)
Heterogeneity: Tau2 = 0.14; Chi2 = 11.38, df = 5 (P = 0.04); I2 =56%
Test for overall effect: Z = 1.55 (P = 0.12)
Test for subgroup differences: Chi2 = 0.27, df = 1 (P = 0.60), I2 =0.0%
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Analysis 2.3. Comparison 2 Antibiotics versus control for the treatment of sore throat: symptom of fever,
Outcome 3 Symptom of fever on day 3: children compared with adults.
Review: Antibiotics for sore throat
Comparison: 2 Antibiotics versus control for the treatment of sore throat: symptom of fever
Outcome: 3 Symptom of fever on day 3: children compared with adults
Study or subgroup Antibiotics Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Symptom of fever on day 3: children
Krober 1985 0/15 0/11 Not estimable
Nelson 1984 12/17 10/18 36.0 % 1.27 [ 0.76, 2.13 ]
Subtotal (95% CI) 32 29 36.0 % 1.27 [ 0.76, 2.13 ]
Total events: 12 (Antibiotics), 10 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.91 (P = 0.36)
2 Symptom of fever on day 3: adults
Brink 1951 34/277 40/198 37.1 % 0.61 [ 0.40, 0.92 ]
Catanzaro 1954 3/62 24/59 26.8 % 0.12 [ 0.04, 0.37 ]
Subtotal (95% CI) 339 257 64.0 % 0.29 [ 0.06, 1.51 ]
Total events: 37 (Antibiotics), 64 (Placebo)
Heterogeneity: Tau2 = 1.22; Chi2 = 7.30, df = 1 (P = 0.01); I2 =86%
Test for overall effect: Z = 1.47 (P = 0.14)
Total (95% CI) 371 286 100.0 % 0.51 [ 0.18, 1.46 ]
Total events: 49 (Antibiotics), 74 (Placebo)
Heterogeneity: Tau2 = 0.73; Chi2 = 17.67, df = 2 (P = 0.00015); I2 =89%
Test for overall effect: Z = 1.25 (P = 0.21)
Test for subgroup differences: Chi2 = 2.80, df = 1 (P = 0.09), I2 =64%
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Analysis 2.4. Comparison 2 Antibiotics versus control for the treatment of sore throat: symptom of fever,
Outcome 4 Symptom of fever at 1 week (6 to 8 days).
Review: Antibiotics for sore throat
Comparison: 2 Antibiotics versus control for the treatment of sore throat: symptom of fever
Outcome: 4 Symptom of fever at 1 week (6 to 8 days)
Study or subgroup Antibiotics Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Brink 1951 0/277 0/198 Not estimable
Denny 1950 0/157 0/50 Not estimable
Landsman 1951 0/52 0/43 Not estimable
Total (95% CI) 486 291 Not estimable
Total events: 0 (Antibiotics), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 Antibiotics versus control for the treatment of sore throat: symptom of
headache, Outcome 1 Symptom of headache on day 3.
Review: Antibiotics for sore throat
Comparison: 3 Antibiotics versus control for the treatment of sore throat: symptom of headache
Outcome: 1 Symptom of headache on day 3
Study or subgroup Antibiotics Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Brink 1951 61/277 80/198 40.1 % 0.55 [ 0.41, 0.72 ]
Denny 1953 54/157 30/50 38.7 % 0.57 [ 0.42, 0.78 ]
El-Daher 1991 7/118 37/111 21.1 % 0.18 [ 0.08, 0.38 ]
Total (95% CI) 552 359 100.0 % 0.44 [ 0.27, 0.71 ]
Total events: 122 (Antibiotics), 147 (Placebo)
Heterogeneity: Tau2 = 0.13; Chi2 = 8.71, df = 2 (P = 0.01); I2 =77%
Test for overall effect: Z = 3.39 (P = 0.00069)
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 Antibiotics versus control for the treatment of sore throat: symptom of
headache, Outcome 2 Symptom of headache on day 3: blinded versus unblinded studies.
Review: Antibiotics for sore throat
Comparison: 3 Antibiotics versus control for the treatment of sore throat: symptom of headache
Outcome: 2 Symptom of headache on day 3: blinded versus unblinded studies
Study or subgroup Antibiotics Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Symptom headache on day 3: blinded studies
Denny 1953 54/157 30/50 38.7 % 0.57 [ 0.42, 0.78 ]
El-Daher 1991 7/118 37/111 21.1 % 0.18 [ 0.08, 0.38 ]
Subtotal (95% CI) 275 161 59.9 % 0.33 [ 0.09, 1.20 ]
Total events: 61 (Antibiotics), 67 (Placebo)
Heterogeneity: Tau2 = 0.77; Chi2 = 9.71, df = 1 (P = 0.002); I2 =90%
Test for overall effect: Z = 1.68 (P = 0.094)
2 Symptom of headache on day 3: unblinded studies
Brink 1951 61/277 80/198 40.1 % 0.55 [ 0.41, 0.72 ]
Subtotal (95% CI) 277 198 40.1 % 0.55 [ 0.41, 0.72 ]
Total events: 61 (Antibiotics), 80 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 4.27 (P = 0.000020)
Total (95% CI) 552 359 100.0 % 0.44 [ 0.27, 0.71 ]
Total events: 122 (Antibiotics), 147 (Placebo)
Heterogeneity: Tau2 = 0.13; Chi2 = 8.71, df = 2 (P = 0.01); I2 =77%
Test for overall effect: Z = 3.39 (P = 0.00069)
Test for subgroup differences: Chi2 = 0.54, df = 1 (P = 0.46), I2 =0.0%
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Analysis 4.1. Comparison 4 Antibiotics versus placebo for the treatment of sore throat: incidence of
complications, Outcome 1 Incidence of acute rheumatic fever within 2 months. Rheumatic fever defined by
clinical diagnosis.
Review: Antibiotics for sore throat
Comparison: 4 Antibiotics versus placebo for the treatment of sore throat: incidence of complications
Outcome: 1 Incidence of acute rheumatic fever within 2 months. Rheumatic fever defined by clinical diagnosis
Study or subgroup Antibiotics Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Dagnelie 1996 0/121 0/118 Not estimable
Pichichero 1987 0/59 0/58 Not estimable
Zwart 2000 0/358 0/164 Not estimable
Little 1997 0/454 0/216 Not estimable
Bennike 1951 0/238 0/268 Not estimable
Brumfitt 1957 0/62 0/59 Not estimable
Chapple 1956 0/186 0/97 Not estimable
De Meyere 1992 0/87 0/94 Not estimable
Leelarasamee 2000 0/369 0/386 Not estimable
Chamovitz 1954 0/257 2/109 5.8 % 0.09 [ 0.00, 1.76 ]
Denny 1950 2/798 17/804 15.8 % 0.12 [ 0.03, 0.51 ]
Wannamaker 1951 5/978 35/996 22.9 % 0.15 [ 0.06, 0.37 ]
Siegel 1961 0/605 2/608 5.8 % 0.20 [ 0.01, 4.18 ]
Brink 1951 2/277 5/198 14.1 % 0.29 [ 0.06, 1.46 ]
Denny 1953 2/157 1/50 8.5 % 0.64 [ 0.06, 6.88 ]
Catanzaro 1954 26/650 12/220 27.0 % 0.73 [ 0.38, 1.43 ]
Total (95% CI) 5656 4445 100.0 % 0.27 [ 0.12, 0.60 ]
Total events: 37 (Antibiotics), 74 (Placebo)
Heterogeneity: Tau2 = 0.51; Chi2 = 12.20, df = 6 (P = 0.06); I2 =51%
Test for overall effect: Z = 3.20 (P = 0.0014)
Test for subgroup differences: Not applicable
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Analysis 4.2. Comparison 4 Antibiotics versus placebo for the treatment of sore throat: incidence of
complications, Outcome 2 Incidence of acute rheumatic fever within 2 months. Penicillin versus placebo.
Review: Antibiotics for sore throat
Comparison: 4 Antibiotics versus placebo for the treatment of sore throat: incidence of complications
Outcome: 2 Incidence of acute rheumatic fever within 2 months. Penicillin versus placebo
Study or subgroup Antibiotics Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bennike 1951 0/238 0/268 Not estimable
Brink 1951 2/197 5/198 12.2 % 0.40 [ 0.08, 2.05 ]
Brumfitt 1957 0/62 0/59 Not estimable
Catanzaro 1954 12/420 12/220 33.2 % 0.52 [ 0.24, 1.15 ]
Chamovitz 1954 0/257 2/109 4.0 % 0.09 [ 0.00, 1.76 ]
Chapple 1956 0/99 0/97 Not estimable
Dagnelie 1996 0/121 0/118 Not estimable
De Meyere 1992 0/87 0/94 Not estimable
Denny 1950 2/798 17/804 14.5 % 0.12 [ 0.03, 0.51 ]
Denny 1953 1/53 1/50 4.8 % 0.94 [ 0.06, 14.68 ]
Pichichero 1987 0/59 0/58 Not estimable
Siegel 1961 0/605 2/608 4.0 % 0.20 [ 0.01, 4.18 ]
Wannamaker 1951 5/978 35/996 27.3 % 0.15 [ 0.06, 0.37 ]
Zwart 2000 0/358 0/164 Not estimable
Total (95% CI) 4332 3843 100.0 % 0.27 [ 0.14, 0.50 ]
Total events: 22 (Antibiotics), 74 (Placebo)
Heterogeneity: Tau2 = 0.15; Chi2 = 7.61, df = 6 (P = 0.27); I2 =21%
Test for overall effect: Z = 4.16 (P = 0.000032)
Test for subgroup differences: Not applicable
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Analysis 4.3. Comparison 4 Antibiotics versus placebo for the treatment of sore throat: incidence of
complications, Outcome 3 Incidence of acute rheumatic fever within 2 months: early (pre-1975) versus late
studies (post-1975).
Review: Antibiotics for sore throat
Comparison: 4 Antibiotics versus placebo for the treatment of sore throat: incidence of complications
Outcome: 3 Incidence of acute rheumatic fever within 2 months: early (pre-1975) versus late studies (post-1975)
Study or subgroup Antibiotics Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Incidence of acute rheumatic fever within 2 months: early (pre-1975) studies
Bennike 1951 0/238 0/268 Not estimable
Brink 1951 2/277 5/198 14.1 % 0.29 [ 0.06, 1.46 ]
Brumfitt 1957 0/62 0/59 Not estimable
Catanzaro 1954 26/650 12/220 27.0 % 0.73 [ 0.38, 1.43 ]
Chamovitz 1954 0/257 2/109 5.8 % 0.09 [ 0.00, 1.76 ]
Chapple 1956 0/186 0/97 Not estimable
Denny 1950 2/798 17/804 15.8 % 0.12 [ 0.03, 0.51 ]
Denny 1953 2/157 1/50 8.5 % 0.64 [ 0.06, 6.88 ]
Siegel 1961 0/605 2/608 5.8 % 0.20 [ 0.01, 4.18 ]
Wannamaker 1951 5/978 35/996 22.9 % 0.15 [ 0.06, 0.37 ]
Subtotal (95% CI) 4208 3409 100.0 % 0.27 [ 0.12, 0.60 ]
Total events: 37 (Antibiotics), 74 (Placebo)
Heterogeneity: Tau2 = 0.51; Chi2 = 12.20, df = 6 (P = 0.06); I2 =51%
Test for overall effect: Z = 3.20 (P = 0.0014)
2 Incidence of acute rheumatic fever within 2 months: late (post-1975) studies
Dagnelie 1996 0/121 0/118 Not estimable
De Meyere 1992 0/87 0/94 Not estimable
Leelarasamee 2000 0/369 0/386 Not estimable
Little 1997 0/454 0/216 Not estimable
Pichichero 1987 0/59 0/58 Not estimable
Zwart 2000 0/358 0/164 Not estimable
Subtotal (95% CI) 1448 1036 Not estimable
Total events: 0 (Antibiotics), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
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(. . . Continued)
Study or subgroup Antibiotics Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total (95% CI) 5656 4445 100.0 % 0.27 [ 0.12, 0.60 ]
Total events: 37 (Antibiotics), 74 (Placebo)
Heterogeneity: Tau2 = 0.51; Chi2 = 12.20, df = 6 (P = 0.06); I2 =51%
Test for overall effect: Z = 3.20 (P = 0.0014)
Test for subgroup differences: Not applicable
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Analysis 4.4. Comparison 4 Antibiotics versus placebo for the treatment of sore throat: incidence of
complications, Outcome 4 Incidence of otitis media within 14 days. Otitis media defined by clinical diagnosis.
Review: Antibiotics for sore throat
Comparison: 4 Antibiotics versus placebo for the treatment of sore throat: incidence of complications
Outcome: 4 Incidence of otitis media within 14 days. Otitis media defined by clinical diagnosis
Study or subgroup Antibiotics Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bennike 1951 0/238 2/268 4.8 % 0.23 [ 0.01, 4.67 ]
Brink 1951 5/277 13/198 42.6 % 0.27 [ 0.10, 0.76 ]
Chamovitz 1954 0/257 1/109 4.3 % 0.14 [ 0.01, 3.46 ]
Chapple 1956 5/186 5/97 29.7 % 0.52 [ 0.15, 1.76 ]
Dagnelie 1996 0/121 0/118 Not estimable
De Meyere 1992 0/87 0/94 Not estimable
Denny 1953 0/157 2/50 4.8 % 0.06 [ 0.00, 1.32 ]
Little 1997 0/454 1/216 4.3 % 0.16 [ 0.01, 3.89 ]
Pichichero 1987 1/59 0/55 4.3 % 2.80 [ 0.12, 67.32 ]
Taylor 1977 0/131 4/66 5.2 % 0.06 [ 0.00, 1.03 ]
Zwart 2000 0/358 0/164 Not estimable
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(. . . Continued)
Study or subgroup Antibiotics Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total (95% CI) 2325 1435 100.0 % 0.30 [ 0.15, 0.58 ]
Total events: 11 (Antibiotics), 28 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 5.41, df = 7 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 3.59 (P = 0.00033)
Test for subgroup differences: Not applicable
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Analysis 4.5. Comparison 4 Antibiotics versus placebo for the treatment of sore throat: incidence of
complications, Outcome 5 Incidence of otitis media within 14 days: early (pre-1975) versus late studies (post-
1975).
Review: Antibiotics for sore throat
Comparison: 4 Antibiotics versus placebo for the treatment of sore throat: incidence of complications
Outcome: 5 Incidence of otitis media within 14 days: early (pre-1975) versus late studies (post-1975)
Study or subgroup Antibiotics Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Incidence of otitis media within 14 days: early (pre-1975) studies
Bennike 1951 0/238 2/268 4.8 % 0.23 [ 0.01, 4.67 ]
Brink 1951 5/277 13/198 42.6 % 0.27 [ 0.10, 0.76 ]
Chamovitz 1954 0/257 1/109 4.3 % 0.14 [ 0.01, 3.46 ]
Chapple 1956 5/186 5/97 29.7 % 0.52 [ 0.15, 1.76 ]
Denny 1953 0/157 2/50 4.8 % 0.06 [ 0.00, 1.32 ]
Subtotal (95% CI) 1115 722 86.2 % 0.30 [ 0.15, 0.62 ]
Total events: 10 (Antibiotics), 23 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.08, df = 4 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 3.28 (P = 0.0010)
2 Incidence of otitis media within 14 days: late (post-1975) studies
Dagnelie 1996 0/121 0/118 Not estimable
0.002 0.1 1 10 500
Favours antibiotics Favours placebo
(Continued . . . )
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(. . . Continued)
Study or subgroup Antibiotics Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
De Meyere 1992 0/87 0/94 Not estimable
Little 1997 0/454 1/216 4.3 % 0.16 [ 0.01, 3.89 ]
Pichichero 1987 1/59 0/55 4.3 % 2.80 [ 0.12, 67.32 ]
Taylor 1977 0/131 4/66 5.2 % 0.06 [ 0.00, 1.03 ]
Zwart 2000 0/358 0/164 Not estimable
Subtotal (95% CI) 1210 713 13.8 % 0.28 [ 0.03, 2.74 ]
Total events: 1 (Antibiotics), 5 (Placebo)
Heterogeneity: Tau2 = 1.62; Chi2 = 3.30, df = 2 (P = 0.19); I2 =39%
Test for overall effect: Z = 1.10 (P = 0.27)
Total (95% CI) 2325 1435 100.0 % 0.30 [ 0.15, 0.58 ]
Total events: 11 (Antibiotics), 28 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 5.41, df = 7 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 3.59 (P = 0.00033)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.94), I2 =0.0%
0.002 0.1 1 10 500
Favours antibiotics Favours placebo
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Analysis 4.6. Comparison 4 Antibiotics versus placebo for the treatment of sore throat: incidence of
complications, Outcome 6 Incidence of sinusitis within 14 days. Sinusitis defined by clinical diagnosis.
Review: Antibiotics for sore throat
Comparison: 4 Antibiotics versus placebo for the treatment of sore throat: incidence of complications
Outcome: 6 Incidence of sinusitis within 14 days. Sinusitis defined by clinical diagnosis
Study or subgroup Antibiotics Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Chamovitz 1954 1/257 3/109 33.6 % 0.14 [ 0.01, 1.34 ]
Dagnelie 1996 0/121 0/118 Not estimable
De Meyere 1992 0/87 0/84 Not estimable
Denny 1953 0/157 1/50 21.6 % 0.11 [ 0.00, 2.60 ]
Landsman 1951 2/52 0/43 23.4 % 4.15 [ 0.20, 84.21 ]
Little 1997 1/454 0/216 21.4 % 1.43 [ 0.06, 34.98 ]
Pichichero 1987 0/59 0/58 Not estimable
Zwart 2000 0/358 0/164 Not estimable
Total (95% CI) 1545 842 100.0 % 0.48 [ 0.08, 2.76 ]
Total events: 4 (Antibiotics), 4 (Placebo)
Heterogeneity: Tau2 = 1.04; Chi2 = 4.45, df = 3 (P = 0.22); I2 =33%
Test for overall effect: Z = 0.82 (P = 0.41)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours antibiotics Favours placebo
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Analysis 4.7. Comparison 4 Antibiotics versus placebo for the treatment of sore throat: incidence of
complications, Outcome 7 Incidence of quinsy within 2 months. Quinsy defined by clinical diagnosis.
Review: Antibiotics for sore throat
Comparison: 4 Antibiotics versus placebo for the treatment of sore throat: incidence of complications
Outcome: 7 Incidence of quinsy within 2 months. Quinsy defined by clinical diagnosis
Study or subgroup Antibiotics Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bennike 1951 1/238 15/268 31.6 % 0.08 [ 0.01, 0.56 ]
Dagnelie 1996 0/121 2/118 14.1 % 0.20 [ 0.01, 4.02 ]
De Meyere 1992 0/87 0/94 Not estimable
Howe 1997 1/69 0/34 12.8 % 1.50 [ 0.06, 35.88 ]
Landsman 1951 0/52 2/43 14.2 % 0.17 [ 0.01, 3.37 ]
Little 1997 0/454 1/216 12.6 % 0.16 [ 0.01, 3.89 ]
Pichichero 1987 0/59 0/58 Not estimable
Zwart 2000 0/358 3/164 14.7 % 0.07 [ 0.00, 1.26 ]
Total (95% CI) 1438 995 100.0 % 0.15 [ 0.05, 0.47 ]
Total events: 2 (Antibiotics), 23 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.85, df = 5 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 3.26 (P = 0.0011)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favours antibiotics Favours placebo
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Analysis 4.8. Comparison 4 Antibiotics versus placebo for the treatment of sore throat: incidence of
complications, Outcome 8 Incidence of acute glomerulonephritis within 1 month. Acute glomerulonephritis
defined by clinical diagnosis.
Review: Antibiotics for sore throat
Comparison: 4 Antibiotics versus placebo for the treatment of sore throat: incidence of complications
Outcome: 8 Incidence of acute glomerulonephritis within 1 month. Acute glomerulonephritis defined by clinical diagnosis
Study or subgroup Antibiotics Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bennike 1951 0/238 0/268 Not estimable
Brink 1951 0/277 0/198 Not estimable
Brumfitt 1957 0/62 0/59 Not estimable
Chamovitz 1954 0/257 1/109 50.1 % 0.14 [ 0.01, 3.46 ]
Chapple 1956 0/186 0/97 Not estimable
Dagnelie 1996 0/121 0/118 Not estimable
Leelarasamee 2000 0/369 0/386 Not estimable
Little 1997 0/454 0/216 Not estimable
Siegel 1961 0/605 1/605 49.9 % 0.33 [ 0.01, 8.17 ]
Zwart 2000 0/358 0/164 Not estimable
Total (95% CI) 2927 2220 100.0 % 0.22 [ 0.02, 2.08 ]
Total events: 0 (Antibiotics), 2 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.14, df = 1 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 1.32 (P = 0.19)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours antibiotics Favours placebo
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A P P E N D I C E S
Appendix 1. Details of previous searches
For the 2011 update we searched the Cochrane Central Register of Controlled Trials (CENTRAL) 2011, Issue 2, part of The Cochrane
Library, www.thecochranelibrary.com (accessed 18 May 2011), which contains the Cochrane Acute Respiratory Infections Group’s
Specialised Register, MEDLINE (November 2008 to May week 1, 2011) and EMBASE (November 2008 to May 2011).
In the previous update we searched the Cochrane Central Register of Controlled Trials (CENTRAL) and the Database of Abstracts of
Reviews of Effects (DARE) (The Cochrane Library 2008, Issue 4) which contains the Acute Respiratory Infections Group’s Specialised
Register, MEDLINE (January 1966 to November 2008) and EMBASE (January 1990 to November 2008).
MEDLINE and CENTRAL were searched using the search strategy shown below. We combined the MEDLINE search string with
the Cochrane Highly Sensitive Search Strategy for identifying randomised trials in MEDLINE: sensitivity and precision-maximising
version (2008 revision) (Lefebvre 2011). We adapted the search string for EMBASE.
MEDLINE (Ovid)
# 1 explode Pharyngitis/
# 2 pharyngit$.mp.
# 3 explode Nasopharyngitis/
# 4 nasopharyngit$.mp.
# 5 explode Tonsillitis/
# 6 tonsillit$.mp.
# 7 sore throat*.mp.
# 8 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7
# 9 explode Anti-Bacterial Agents/
# 10 antibiot$.mp.
# 11 #9 OR #10
# 12 #8 AND #11
(Embase.com used in 2011 update)
#1. ’pharyngitis’/exp AND [embase]/lim
#2. pharyngit*:ti,ab AND [2004-2008]/py
#3. ’rhinopharyngitis’/exp AND [embase]/lim
#4. rhinopharyngit*:ti,ab OR nasopharyngit*:ti,ab [embase]/lim
#5. ’tonsillitis’/exp AND [embase]/lim
#6. tonsillit*:ti,ab AND [embase]/lim
#7. ’sore throat’/exp AND [embase]/lim
#8. ’sore throat’:ti,ab OR ’sore throats’:ti,ab embase]/lim
#9. #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8
#10. ’antibiotic agent’/exp AND [embase]/lim
#11. antibiotic*:ti,ab AND [embase]/lim
#12. #10 OR #11 619,306
#13. random*:ti,ab OR factorial*:ti,ab OR crossover*:ti,ab OR ’cross over’:ti,ab OR placebo*:ti,ab OR assign*:ti,ab OR allocat*:ti,ab
OR volunteer*:ti,ab AND [embase]/lim
#14. ’double blind’:ti,ab OR ’double blinded’:ti,ab OR ’single blind’:ti,ab OR ’single blinded’:ti,ab AND [embase]/lim
#15. ’crossover procedure’/exp AND [embase]/lim
#16. ’double blind procedure’/exp AND [embase]/lim
#17. ’single blind procedure’/exp AND [embase]/lim
#18. ’randomized controlled trial’/exp AND [embase]/lim
#19. #13 OR #14 OR #15 OR #16 OR #17 OR #18
#20. #9 AND #12 AND #19
(EMBASE search used in earlier versions of the review)
EMBASE (WebSPIRS)
#1 explode ’pharyngitis-’ / all subheadings in DEM,DER,DRM,DRR
67Antibiotics for sore throat (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
#2 (pharyngit* in ti) or (pharyngit* in ab)
#3 explode ’rhinopharyngitis-’ / all subheadings in DEM,DER,DRM,DRR
#4 (nasopharyngit* in ti) or (nasopharyngit* in ab)
#5 explode ’tonsillitis-’ / all subheadings in DEM,DER,DRM,DRR
#6 (tonsillit* in ti) or (tonsillit* in ab)
#7 explode ’sore-throat’ / all subheadings in DEM,DER,DRM,DRR
#8 (sore throat in ti) or (sore throat in ab)
#9 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8
#10 ’antibiotic-agent’ / all subheadings in DEM,DER,DRM,DRR
#11 (antibiotic* in ti) or (antibiotic* in ab)
#12 #10 or #11
#13 #9 and #12
#14 explode ’randomized-controlled-trial’ / all subheadings
#15 explode ’controlled-study’ / all subheadings
#16 explode ’single-blind-procedure’ / all subheadings
#17 explode ’double-blind-procedure’ / all subheadings
#18 explode ’crossover-procedure’ / all subheadings
#19 explode ’phase-3-clinical-trial’ / all subheadings
#20 (randomi?ed controlled trial in ti) or (randomi?ed controlled trial in ab)
#21 ((random* or placebo* or double-blind*)in ti) or ((random* or placebo* or double-blind*)in ab)
#22 (controlled clinical trial* in ti) or (controlled clinical trial* in ab)
#23 (explode ’randomized-controlled-trial’ / all subheadings) or (explode ’controlled-study’ / all subheadings) or (explode ’single-blind-
procedure’ / all subheadings) or (explode ’double-blind-procedure’ / all subheadings) or (explode ’crossover-procedure’ / all subheadings)
or (explode ’phase-3-clinical-trial’ / all subheadings) or ((randomi?ed controlled trial in ti) or (randomi?ed controlled trial in ab)) or
(((random* or placebo* or double-blind*)in ti) or ((random* or placebo* or double-blind*)in ab)) or ((controlled clinical trial* in ti)
or (controlled clinical trial* in ab))
#24 (nonhuman in der) not ((human in der)and (nonhuman in der))
#25 ((explode ’randomized-controlled-trial’ / all subheadings) or (explode ’controlled-study’ / all subheadings) or (explode ’single-blind-
procedure’ / all subheadings) or (explode ’double-blind-procedure’ / all subheadings) or (explode ’crossover-procedure’ / all subheadings)
or (explode ’phase-3-clinical-trial’ / all subheadings) or ((randomi?ed controlled trial in ti) or (randomi?ed controlled trial in ab)) or
(((random* or placebo* or double-blind*)in ti) or ((random* or placebo* or double-blind*)in ab)) or ((controlled clinical trial* in ti)
or (controlled clinical trial* in ab))) not ((nonhuman in der) not ((human in der)and (nonhuman in der)))
#26 #13 and #25
Appendix 2. EMBASE (Elsevier) search strategy
#16 #11 AND #15
#15 #12 OR #13 OR #14
#14 azithromycin*:ab,ti OR clarithromycin*:ab,ti OR erythromycin*:ab,ti OR roxithromycin*:ab,ti ORmacrolide*:ab,ti OR cefaman-
dole*:ab,ti OR cefoperazone*:ab,ti OR cefazolin*:ab,ti OR cefonicid*:ab,ti OR
cefsulodin*:ab,ti OR cephacetrile*:ab,ti OR cefotaxime*:ab,ti OR cephalothin*:ab,ti OR cephapirin*:ab,ti OR cephalexin*:ab,ti OR
cephaclor*:ab,ti OR cephadroxil*:ab,ti OR cephaloglycin*:ab,ti OR
cephradine*:ab,ti OR cephaloridine*:ab,ti OR ceftazidime*:ab,ti OR cephamycin*:ab,ti OR cefmetazole*:ab,ti OR cefotetan*:ab,ti OR
cefoxitin*:ab,ti OR cephalosporin*:ab,ti OR cefpodoxime*:ab,ti OR
cefuroxime*:ab,ti OR cefixime*:ab,ti OR amoxicillin*:ab,ti OR amoxycillin*:ab,ti OR ampicillin*:ab,ti OR sulbactum*:ab,ti OR tetra-
cyclin*:ab,ti OR clindamycin*:ab,ti OR lincomycin*:ab,ti OR doxycyclin*:ab,ti OR fluoroquinolone*:ab,ti OR ciprofloxacin*:ab,ti
OR fleroxacin*:ab,ti OR enoxacin*:ab,ti OR norfloxacin*:ab,ti OR ofloxacin*:ab,ti OR pefloxacin*:ab,ti OR moxifloxacin*:ab,ti OR
esparfloxacin*:ab,ti OR clindamicin*:ab,ti OR penicillin*:ab,ti OR ticarcillin*:ab,ti OR ’beta-lactam’:ab,ti OR ’beta-lactams’:ab,ti OR
levofloxacin*:ab,ti OR trimethoprim*:ab,ti OR ’co-trimoxazole’:ab,ti
#13 antibiot*:ab,ti
#12 ’antibiotic agent’/exp
#11 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10
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#10 (sore* NEAR/2 throat*):ab,ti
#9 ((throat* OR pharyn*) NEAR/3 (infect* OR inflam* OR strep*)):ab,ti
#8 ’sore throat’/de
#7 (tonsil* NEAR/2 (infect* OR inflam*)):ab,ti
#6 tonsillit*:ab,ti
#5 ’tonsillitis’/exp
#4 rhinopharyngit*:ab,ti OR nasopharyngit*:ab,ti
#3 ’rhinopharyngitis’/de
#2 pharyngit*:ab,ti
#1 ’pharyngitis’/exp
F E E D B A C K
Antibiotics for sore throat
Summary
1. The objectives as they are stated in the abstract include an assessment of the harms associated with the use of antibiotics in the
management of sore throat, but the objectives as stated in the text of the review no longer refer to any assessment of harm. Indeed, the
review does not address any adverse effects of antibiotics [which are not unimportant] and does not provide a reasonable explanation as
to why this is not done other than to state in the discussion that this was not possible because of inconsistencies in the way these data
were recorded. In the absence of RCT data on harmful effects the authors might have considered whether usable information could be
provided by other study designs.
2. Reviews on this subject should treat adults and children separately, but this review does not attempt to do this.
3. All clinically important outcomes have not been addressed by the review and others such as resource use, re-attendance and time off
school or work are probably at least as important as those that were selected. It may have been more helpful to have collected data on
all available outcomes provided that they are free from detection bias.
4. The question addressed by the review is not sufficiently well defined to allow the review to be executed systematically. Clear definitions
are not given for the key elements of the question.
Most importantly, clear definitions of what is meant by primary care and sore throat are not given, leading to confusion around inclusion
and exclusion decisions. Many of the control groups of the included studies do not involve a placebo but instead simply compare
treatment with antibiotics to no treatment, so that some excluded studies would be eligible for inclusion, such as Catanzaro 1958 which
was excluded because it compared antibiotics with sulfadiazine.
Apparent errors in inclusion and exclusion decisions have arisen probably as a result of the general lack of clarity discussed above.
Specifically, the lack of a clear definition of what is meant by primary care appears to have led to the inclusion of an odd assortment of
studies. For example, a couple of the included trials studied only people with sore throat who were admitted to hospital (Siegal 1961
and Bennike 1951). In addition, there appears to be an issue around the definition of a sore throat particularly in relation to positive or
negative Streptococcus throat swabs. Streptococcal sore throats are a small sub-set of the total population of sore throats and the failure
of the reviewers to address this in the inclusion criteria means that the results of pragmatic trials of sore throat are mixed in with those
of
streptococcal sore throat.
There is a failure to always faithfully report the detailed results of the included studies, and there are several numerical errors in the
data abstracted. For example, in Bennike 1951 the baseline numbers include patients in the “ulcerative tonsillitis” group even though
most outcomes are not reported for this group.
5. The search strategy is restricted to a Medline search, a search of the Cochrane Library and citation checking. No attempt appears to
have been made to search other databases. The reviewers are not explicit about the details of their searching activities nor about how
they used the work of the Cochrane Acute Respiratory Infections Group.
6. References to the included and excluded studies were incomplete. Specifically they were not provided for Dagnelie 1996, Howie
1997, Little 1997 and Peterson 1997 (included) and Herx 1988, Howie 1970, Marlow 1989, McDonald 1985, Schalen 1993 and
Todd 1984 (excluded).
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7. Given the nature of the data presented, it is possible that a formal meta-analysis was inappropriate. A descriptive analysis may have
been more appropriate and more informative.
8. There is considerable uncertainty around the effectiveness of antibiotics on sore throat on the basis of the existing research examined
by this review and this is not emphasised by the authors. Particular problems exist around the relevance of the trials to the present day
with regard to the outcomes examined (rheumatic fever and glomerulonephritis), the poor quality of the majority of the included trials
and the generalisability of the trials with regard to the study populations (e.g. United States air force recruits).
Jackie Young (on behalf of an interdepartmental critical appraisal workshop based in theDepartment of PublicHealth andEpidemiology,
The University of Birmingham, UK) Email: j.m.young.20@bham.ac.uk
Reply
1. This is valid criticism: we need to describe the inadequacies of the information in the trials (after checking again) in the text.
2. A subgroup analysis on the basis of age is a good idea, and we will attempt this at the next major review.
3. This is a good idea, and we will attempt this at the next major review.
4. Certainly the issue of definitions is particularly difficult in this group of illnesses. One of us has written a paper on these difficulties
(Del Mar C. Managing sore throat: a literature review. I. Making the diagnosis. Med J Aust 1992;156:572-5.). There is a particular
difficulty in the fact that primary care doctors use the terms ’sore throat’ tonsillitis and pharyngitis in slightly different ways, including
interchangeably. Moreover the notion that patients with positive swabs for Streptococcus have a different illness can be challenged.
Nevertheless a subgroup analysis for this with swab-positive and swab-negative is a good idea which we will incorporate with our next
review.
Thank for pointing numerical errors out to us, and we will check on this. Please could you detail other numerical errors for us?
5. We are explicit about our search method. At the time we undertook the search the Cochrane Acute Respiratory Infections Group
had no material to assist us. This will be reviewed at the next major update.
6. Thank you for drawing our attention to this.
7. As is often the case, there is considerable variation in the population groups, treatments, outcomes measures, etc in these trials. This
does not make a synthesis inappropriate, but rather allows us to examine whether these factors appear to make a difference. We also
felt it important to specifically attempt to calculate the SIZE of the benefits, as this is what clinicians are interested in, and what will
persuade them to modify their practice. It is then important to recognise that the size of the effect will vary in different populations:
as we point out, in groups at high risk of rheumatic fever - such as Australian aboriginals - the prevention of RF is important; we are
also interested in trying to better predict which sub-groups will experience the most or least symptom relief, and plan to detail this in
the next update.
8. We think we have discussed this in the Review. However we will reconsider what we have written in the overhaul.
Contributors
The review team.
Antibiotics for sore throat
Summary
I noticed that trials with no events in either groups are not (cannot) be part of the pooled estimates. Although I see there is a statistical/
technical problem here it does not seem right. It appears to imply that no events is no evidence. I wonder whether it is defensible to
add one event in both groups and add the evidence as one would normally do?
Gerben ter Riet
I certify that I have no affiliations with or involvement in any organisation or entity with a direct financial interest in the subject matter
of my criticisms.
Reply
Many thanks for this. We have gone back and checked with statisticians about your point. The issue seems to be:
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1. Whether empty cells are a problem. The concern is that because one cannot divide anything by zero, this might represent a problem.
We think not, because in no forest plots are there totals with zero--except for acute glomerulonephritis (there were no cases in the
intervention arms of any trials, and only two in the control arms).
2.Whether the empty cells represent no evidence or evidence of no effect.We only recoded a zero where the study declared the outcome.
Thus we assume that “no events” implies no events, rather than no reporting of events that might have occurred.
We have reported in Peto Odds ratios, the best measure for rare events.
Contributors
Chris Del Mar
Typographical error in the Abstract, 26 August 2008
Summary
Feedback: There seems to be a printing error in the abstract: the total number of cases according to the full text is 12835, but the
number given in the abstract is 2835.
Martti Teikari (Feedback comment submitted 27 August 2008)
Reply
Many thanks. We will correct the typing error.
Contributors
Chris Del Mar
Antibiotics for sore throat, 30 December 2013
Summary
Comment: This work is important and useful. I have 2 concerns. First is a value judgment about the size of the treatment effect,
especially concerning quinsy. Second, is the exclusion of other causes of adolescent and young adult pharyngitis - group C (see Zwart
2000) strep and Fusobacterium necrophorum. Adolescents and young adults have a significant risk of suppurative complications, and
most are not due to group A strep. A complete review in 2014 should acknowledge that sore throat in those age groups include other
bacterial causes.
I agree with the conflict of interest statement below:
I certify that I have no affiliations with or involvement in any organization or entity with a financial interest in the subject matter of
my feedback.
Robert Centor
Professor Internal Medicine
University of Alabama at Birmingham
Reply
We thank Dr Centor for commenting on the review with his thoughtful points.
1. Our comment on the size of the reduction of the complication of quinsy
The comments we made in the review are these:
“Antibiotics are effective at reducing the relative complication rate of people suffering sore throat. However, the relative benefit
exaggerates the absolute benefit because complication rates are low and the illness is short-lived. Interpretation of these data is aided by
estimating the absolute benefit, which we attempt below.
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In these trials, conducted mostly in the 1950s, for every 100 participants treated with antibiotics rather than placebo, there was one
fewer case of acute rheumatic fever, two fewer cases of acute otitis media and three fewer cases of quinsy. These figures need to be
adapted to current circumstances and individuals. For example, the complication rate of acute otitis media among those with sore
throats before 1975 was 3%. A NNTB of about 50 to prevent one case of acute otitis media can be estimated from the data. After
1975, this complication rate fell to 0.7% and applying the odds of reducing the complication with antibiotics from the data table yields
a NNTB of nearly 200 to prevent one case of acute otitis media. Clinicians will have to exercise judgement in applying these data to
their patients….”
In other words we think that it is important to keep in mind the incidence of complications (and the absolute risk reduction we can
expect from antibiotics) rather than simply focus on the relative risk reduction. In clinical settings (such as low-income countries, and
in Australia for example among indigenous communities) where complications are much more common, then clinicians will interpret
the finding of this review by increasing the threshold for using antibiotics.
We also, incidentally, mention under “Agreements and disagreements with other studies or reviews” that “A recent review analysing the
risk-benefit profile of antimicrobial prescribing for children concluded that antibiotics show little benefit in preventing quinsy following
sore throat (Keith 2010).”
2. Exclusion of the other aetiological agents of sore throat such as Group C Streptococcus and Fusobacterium necrophorum.
It is certainly true that there are many aetiological agents other than Group A beta haemolytic Streptococcus (GABHS), including a
huge range of viruses and bacteria, and even non-infective causes. However two factors influence the review:
a) The enormous focus on acute rheumatic fever as a complication, which for decades was the over-riding indication, and the single
reason proposed by researchers and clinicians for using penicillin for sore throat. This was the motivation for an enormous search to
find the best way of identifying GABHS, (and incidentally the reason why your own work on predictors of GABHS was so important).
b) The availability of randomised controlled trials that addressed these agents.
In future updates, any new RCTs that address other aetiological agents will be eligible for inclusion, as can be seen from our inclusion
and exclusion criteria.
Contributors
Anneliese Spinks (Feedback reply submitted 24 January 2014)
Antibiotics for sore throat, 26 September 2016
Summary
Thank you for your informative review. A previous review on, generally, the same topic was conducted by Robertson et al. (1) which
included n = 10 trials. Would you comment on why the following two citations included in Robertson et al. do not appear either as
included or excluded references in your review?
- Brock LL, Siegel AC. Studies on the prevention of rheumatic fever: the effect of time of initiation of treatment of streptococcal
infections on the immune response of the host. J Clin Invest 1953, 32:630-632.
- Houser HB, Eckhardt GC, Hahn EO, Denny FW, Wannamaker LW, Rammelkamp CH: Effect of aureomycin treatment of strepto-
coccal sore throat on the streptococcal carrier state, the immunologic response of the host, and the incidence of acute rheumatic fever.
Pediatrics 1953, 12(6):593-606.
Thanks,
Marlys LeBras BSP, ACPR, PharmD
References:
1. Robertson KA, Volmink JA, Mayosi BM. Antibiotics for the primary prevention of acute rheumatic fever: a meta-analysis. BMC
Cardiovascular Disorders 2005;5:11.
I do not have any affiliation with or involvement in any organisation with a financial interest in the subject matter of my comment
Reply
We would like to thank you for alerting us to the omission of these early research studies in our review. We will seek to redress this in
our coming update by reviewing the studies against our inclusion / exclusion criteria and revising the results accordingly if these studies
do meet the inclusion criteria.
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Contributors
Anneliese Spinks
WH A T ’ S N E W
Last assessed as up-to-date: 11 July 2013.
Date Event Description
6 October 2016 Feedback has been incorporated Feedback added.
H I S T O R Y
Protocol first published: Issue 1, 1997
Review first published: Issue 2, 1997
Date Event Description
28 January 2014 Feedback has been incorporated Feedback comment and author reply added to the re-
view.
11 July 2013 New search has been performed Searches conducted.We did not identify any new trials
for inclusion but we excluded three new trials (Kapur
2011; Kolobukhina 2011; Supajatura 2012).
11 July 2013 New citation required but conclusions have not
changed
Our conclusions remain unchanged.
18 May 2011 New search has been performed Searches conducted. No new studies were identified
and our conclusions remain unchanged
17 February 2010 Amended Contact details updated.
21 January 2010 Amended Contact details updated.
25 November 2008 New search has been performed Searches conducted. No new studies were identified
and conclusions remain unchanged
27 August 2008 Feedback has been incorporated Typographical error in the Abstract corrected.
12 July 2008 Amended Converted to new review format.
18 October 2006 Feedback has been incorporated Feedback added.
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(Continued)
9 March 2006 New search has been performed In this 2006 update there is an addition of data from
one new study by Zwart 2003.
Additionally, reported statistics were changed from
odds ratios to more clinically meaningful relative risks
(using a random-effects model).
Since the update for this review was submitted to
The Cochrane Library (Issue 4, 2006), we have been
alerted to an error in the data extraction. This error
involved switching the number of participants experi-
encingheadache onday three between the intervention
and placebo groups for the study by El-Daher 1991.
We therefore incorrectly concluded that antibiotics
conferred no benefit for the symptom of headache,
whereas in fact the meta-analysis does show a signifi-
cant protective effect (RR 0.47; 95% CI 0.38 to 0.58)
22 May 2003 New search has been performed Searches conducted.
8 May 2000 New search has been performed Searches conducted.
30 June 1999 New search has been performed Searches conducted.
31 March 1996 New search has been performed Searches conducted.
C O N T R I B U T I O N S O F A U T H O R S
Chris Del Mar first conceived the review, presenting it as a meta-analysis in a journal (Del Mar 1992a; Del Mar 1992b). It was
subsequently improved and modified forThe Cochrane Librarywith Paul Glasziou (who improved the subgroup analyses) and Anneliese
Spinks (who updated searches and completed the analyses).
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Paul Glasziou is on the board of Therapeutic Guidelines Limited and holds a research grant from the NHMRC on antibiotic resistance.
Chris Del Mar has received funding from the NHMRC for antibiotic resistance, funding the ARI Cochrane Group, and from some
consultancies (GSK for advice about vaccines for otitis media; and a local pharmaceutical company contemplating analgesic ear drops
for otitis media).
Anneliese Spinks does not have any interests to declare relevant to this review.
74Antibiotics for sore throat (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
S O U R C E S O F S U P P O R T
Internal sources
• Bond University (2006 update), Australia.
• University of Oxford, UK.
• Griffith University, Australia.
External sources
• NHS support, UK.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Anti-Bacterial Agents [∗therapeutic use]; Pharyngitis [∗drug therapy]; Randomized Controlled Trials as Topic; Rheumatic Fever [pre-
vention & control]
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